Cochrane
Library

Cochrane Database of Systematic Reviews

Interventions for managing medication-related osteonecrosis of the jaw (Review)

Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O

Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O.
Interventions for managing medication-related osteonecrosis of the jaw.
Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD012432.
DOI: [10.1002/14651858.CD012432.pub2](https://doi.org/10.1002/14651858.CD012432.pub2).

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	8
OBJECTIVES	11
METHODS	11
RESULTS	14
Figure 1.	15
Figure 2.	17
DISCUSSION	19
AUTHORS' CONCLUSIONS	20
ACKNOWLEDGEMENTS	21
REFERENCES	22
CHARACTERISTICS OF STUDIES	27
DATA AND ANALYSES	38
Analysis 1.1. Comparison 1 Dental examinations at three-month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 1 MRONJ (incidence proportion).	39
Analysis 1.2. Comparison 1 Dental examinations at three-month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 2 MRONJ (incidence rate: MRONJ cases per patient-year).	39
Analysis 2.1. Comparison 2 A dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) versus a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions, Outcome 1 MRONJ (incidence proportion).	39
Analysis 3.1. Comparison 3 Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ, Outcome 1 Healing of MRONJ at last contact.	40
Analysis 4.1. Comparison 4 Autofluorescence-guided bone surgery (experimental) versus tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ, Outcome 1 Healing of MRONJ (defined as mucosal integrity) at 1 year.	40
ADDITIONAL TABLES	41
APPENDICES	41
CONTRIBUTIONS OF AUTHORS	44
DECLARATIONS OF INTEREST	44
SOURCES OF SUPPORT	45
INDEX TERMS	45

[Intervention Review]

Interventions for managing medication-related osteonecrosis of the jaw

Natalie H Beth-Tasdogan¹, Benjamin Mayer², Heba Hussein³, Oliver Zolk¹

¹Institute of Pharmacology of Natural Products & Clinical Pharmacology, Ulm University, Ulm, Germany. ²Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany. ³Department of Oral Medicine, Diagnosis, and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt

Contact address: Oliver Zolk, Institute of Pharmacology of Natural Products & Clinical Pharmacology, Ulm University, Helmholtzstr. 20, Ulm, 89081, Germany. oliver.zolk@uni-ulm.de.

Editorial group: Cochrane Oral Health Group.

Publication status and date: New, published in Issue 10, 2017.

Citation: Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. *Cochrane Database of Systematic Reviews* 2017, Issue 10. Art. No.: CD012432. DOI: [10.1002/14651858.CD012432.pub2](https://doi.org/10.1002/14651858.CD012432.pub2).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and involves the progressive destruction of bone in the mandible or maxilla. Depending on the drug, its dosage, and the duration of exposure, the occurrence of this adverse drug reaction may be rare (e.g. following the oral administration of bisphosphonate or denosumab treatments for osteoporosis, or antiangiogenic agent-targeted cancer treatment) or common (e.g. following intravenous bisphosphonate for cancer treatment). MRONJ is associated with significant morbidity, adversely affects quality of life (QoL), and is challenging to treat.

Objectives

To assess the effects of interventions versus no treatment, placebo, or an active control for the prophylaxis of MRONJ in people exposed to antiresorptive or antiangiogenic drugs.

To assess the effects of non-surgical or surgical interventions (either singly or in combination) versus no treatment, placebo, or an active control for the treatment of people with manifest MRONJ.

Search methods

Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 23 November 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2016, Issue 10), MEDLINE Ovid (1946 to 23 November 2016), and Embase Ovid (23 May 2016 to 23 November 2016). The US National Institutes of Health Trials Registry (ClinicalTrials.gov) and the [World Health Organization International Clinical Trials Registry Platform](http://www.who.int/clinicaltrialsregistryplatform) were searched for ongoing trials. No restrictions were placed on language or publication status when searching the electronic databases; however, the search of Embase was restricted to the last six months due to the Cochrane Embase Project to identify all clinical trials and add them to CENTRAL.

Selection criteria

We included randomised controlled trials (RCTs) comparing one modality of intervention with another for the prevention or treatment of MRONJ. For 'prophylaxis of MRONJ', the primary outcome of interest was the incidence of MRONJ; secondary outcomes were QoL, time-to-event, and rate of complications and side effects of the intervention. For 'treatment of established MRONJ', the primary outcome of interest was healing of MRONJ; secondary outcomes were QoL, recurrence, and rate of complications and side effects of the intervention.

Data collection and analysis

Two review authors independently screened the search results, extracted the data, and assessed the risk of bias in the included studies. For dichotomous outcomes, we reported the risk ratio (RR) (or rate ratio) and 95% confidence intervals (CI).

Main results

We included five RCTs (1218 participants) in the review. Three trials focused on the prophylaxis of MRONJ. Two trials investigated options for the treatment of established MRONJ. The RCTs included only participants treated with bisphosphonates and, thus, did not cover the entire spectrum of medications associated with MRONJ.

Prophylaxis of MRONJ

One trial compared standard care with regular dental examinations in three-month intervals and preventive treatments (including antibiotics before dental extractions and the use of techniques for wound closure that avoid exposure and contamination of bone) in men with metastatic prostate cancer treated with zoledronic acid. The intervention seemed to lower the risk of MRONJ: RR 0.10; 95% CI 0.02 to 0.39 (253 participants; low-quality evidence). Secondary outcomes were not evaluated.

As dentoalveolar surgery is considered a common predisposing event for developing MRONJ, one trial investigated the effect of plasma rich in growth factors (PRGF) for preventing MRONJ in people with cancer undergoing dental extractions. There was insufficient evidence to support or refute a benefit of PRGF on MRONJ incidence when compared with standard treatment (RR 0.08, 95% CI 0.00 to 1.51; 176 participants; very low-quality evidence). Secondary outcomes were not reported. In another trial comparing wound closure by primary intention with wound closure by secondary intention after dental extractions in people treated with oral bisphosphonates (700 participants), no cases of intraoperative complications or postoperative MRONJ were observed. QoL was not investigated.

Treatment of MRONJ

One trial analysed hyperbaric oxygen (HBO) treatment used in addition to standard care (antiseptic rinses, antibiotics, and surgery) compared with standard care alone. HBO in addition to standard care did not significantly improve healing from MRONJ compared with standard care alone (at last follow-up: RR 1.56; 95% CI 0.77 to 3.18; 46 participants included in the analysis; very low-quality evidence). QoL data were presented qualitatively as intragroup comparisons; hence, an effect estimate of treatment on QoL was not possible. Other secondary outcomes were not reported.

The other RCT found no significant difference between autofluorescence- and tetracycline fluorescence-guided sequestrectomy for the surgical treatment of MRONJ at any timepoint (at one-year follow-up: RR 1.05; 95% CI 0.86 to 1.30; 34 participants included in the analysis; very low-quality evidence). Secondary outcomes were not reported.

Authors' conclusions

Prophylaxis of MRONJ

One open-label RCT provided some evidence that dental examinations in three-month intervals and preventive treatments may be more effective than standard care for reducing the incidence of MRONJ in individuals taking intravenous bisphosphonates for advanced cancer. We assessed the certainty of the evidence to be low.

There is insufficient evidence to either claim or refute a benefit of either of the interventions tested for prophylaxis of MRONJ (i.e. PRGF inserted into the postextraction alveolus during dental extractions, and wound closure by primary or secondary intention after dental extractions).

Treatment of MRONJ

Available evidence is insufficient to either claim or refute a benefit for hyperbaric oxygen therapy as an adjunct to conventional therapy. There is also insufficient evidence to draw conclusions about autofluorescence-guided versus tetracycline fluorescence-guided bone surgery.

PLAIN LANGUAGE SUMMARY

Interventions for managing medication-related osteonecrosis (severe bone damage) of the jaw

Review question

What are the effects of different interventions to either prevent or treat medication-related osteonecrosis of the jaw compared with each other or compared with no treatment or an inactive intervention ('placebo')?

Background

Medication-related osteonecrosis of the jaw (MRONJ) is severe bone damage in the jaw bone that occurs in some people as an adverse reaction to certain medicines commonly used in the treatment of cancer and osteoporosis (a disease that makes bones fragile). It is a painful condition that can be difficult to treat. MRONJ occurs rarely in people taking some medicines for osteoporosis. However, in people receiving these drugs at higher doses for cancer-related conditions, the risk of MRONJ may be higher and has been reported to occur in up to 5 in 100 individuals. It is essential to obtain better treatments for people who have MRONJ. It is also important to identify effective preventive measures to reduce the risk of MRONJ.

Study characteristics

Working with [Cochrane Oral Health](#), we searched for studies that had been published up to November 2016. We found three studies that focused on the prevention of MRONJ and two studies that tested treatments for MRONJ. The studies involved 1218 adults, with the smallest study having 40 participants and the largest study having 700 participants. Most study participants were women, but one study was of men with prostate cancer receiving bisphosphonate infusions (given by drip into a vein). All studies included only participants treated with bisphosphonates (used to support treatment and reduce risk of fracture and bone pain), although several other drugs are also known to induce MRONJ.

Key results

One study provided low-quality evidence that dental examinations at three-month intervals and preventive treatments (antibiotics before dental extractions and the use of techniques for wound closure that avoid exposure and contamination of bone) are more effective than standard care for reducing the number of cases with MRONJ in a group of people receiving intravenous bisphosphonates for cancer-related conditions. In the experimental group (which received preventive care consisting of antibiotics and specific wound closure), fewer people developed MRONJ (2 participants per 100 who underwent close monitoring) compared with the control group (23 participants per 100 who had standard care).

There was insufficient evidence to conclude that the use of the other interventions investigated would reduce the risk of MRONJ or would improve healing of MRONJ.

Quality of evidence

The quality of evidence was low or very low. This was due to limitations in how the studies were designed and run. For example, some participants changed groups during the study, some participants did not finish the study, and the outcomes were measured at different follow-up times.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Dental examinations at three-month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ

Dental examinations at three-month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ

Population: prophylaxis of MRONJ

Setting: hospital

Intervention: dental examinations at three-month intervals and preventive treatments (experimental)

Comparison: standard care (control)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with standard care (control)	Risk with dental examinations at three-month intervals and preventive treatments (experimental)				
MRONJ (incidence proportion) Diagnostic criteria for MRONJ: non-healing exposed bone in mandible or maxilla for longer than 8 weeks without any change of the stage of disease (follow-up: mean 32 months)	233 per 1000	23 per 1000 (5 to 91)	RR 0.10 (0.02 to 0.39)	253 (1 RCT)	⊕⊕⊕⊖ LOW ¹	Participants: high-risk (i.e. individuals with cancer exposed to intravenous zoledronic acid) The outcome MRONJ was also reported as number of cases per patient-year (incidence rate) rate ratio 0.18 (95% CI 0.04 to 0.74)

***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
CI: confidence interval; **RR:** risk ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1. We downgraded the quality of the evidence by two levels due to very serious risk of bias (high and unbalanced rate of crossovers after randomisation, high drop-out rates due to high mortality, failure to adhere to the intention-to-treat principle, the mean follow-up differed between experimental and control group).

MRONJ = medication-related osteonecrosis of the jaw
RCT = randomised controlled trial

Summary of findings 2. A dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions

A dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions

Population: people treated with IV bisphosphonates who need dental extractions

Setting: hospital

Intervention: a dental extraction protocol with PRGF (experimental)

Comparison: a standard dental extraction protocol without PRGF (control)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with a standard dental extraction protocol without PRGF (control)	Risk with a dental extraction protocol with PRGF (experimental)				
MRONJ (incidence proportion) Diagnostic criteria of MRONJ: pain, swelling, and non-healing exposed necrotic bone or fistulae, or both, with connection to the bone (follow-up: 24-60 months)	59 per 1000	5 per 1000 (0 to 89)	RR 0.08 (0.00 to 1.51)	176 (1 RCT)	⊕⊕⊕⊕ VERY LOW ¹	Participants: high risk, i.e. individuals with cancer exposed to IV zoledronic acid

***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1. We downgraded the quality of the evidence by three levels due to imprecision and very serious risk of bias (high or unclear risk of selection bias, performance bias, detection bias, and attrition bias).

IV = intravenous

MRONJ = medication-related osteonecrosis of the jaw

RCT = randomised controlled trial

Summary of findings 3. Hyperbaric oxygen therapy as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ

Hyperbaric oxygen therapy as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ

Population: treatment of MRONJ

Setting: hospital

Intervention: hyperbaric oxygen therapy as an adjunct to conventional therapy (experimental)

Comparison: conventional therapy (control)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with conventional therapy (control)	Risk with hyperbaric oxygen therapy as an adjunct to conventional therapy (experimental)				
Healing of MRONJ Diagnostic criteria for healing of MRONJ: gingival coverage with no exposed bone (follow-up: up to 24 months (outcome was measured at last follow-up))	333 per 1000	520 per 1000 (257 to 1000)	RR 1.56 (0.77 to 3.18)	46 participants included in the analysis (1 RCT)	⊕⊕⊕⊕ VERY LOW ¹	

***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).
CI: confidence interval; **RR:** risk ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1. We downgraded the quality of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, detection bias, and attrition bias; failure to adhere to the intention-to-treat principle).

MRONJ = medication-related osteonecrosis of the jaw

RCT = randomised controlled trial

Summary of findings 4. Autofluorescence-guided bone surgery (experimental) compared to tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ

Autofluorescence-guided bone surgery (experimental) compared to tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ

Population: treatment of MRONJ

Setting: hospital

Intervention: autofluorescence-guided bone surgery (experimental)

Comparison: tetracycline fluorescence-guided bone surgery (control)

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with tetracycline fluorescence-guided bone surgery (control)	Risk with autofluorescence-guided bone surgery (experimental)				
Healing of MRONJ Criteria for healing of MRONJ: mucosal integrity (follow-up: 1 year)	889 per 1000	933 per 1000 (764 to 1000)	RR 1.05 (0.86 to 1.30)	34 participants included in the analysis (1 RCT)	⊕⊕⊕⊕ VERY LOW ¹	

***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **RR:** risk ratio; **OR:** odds ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1. We downgraded the quality of the evidence by three levels due to imprecision and very serious risk of bias (unclear and high risk of selection bias, performance bias, and detection bias).

MRONJ = medication-related osteonecrosis of the jaw

RCT = randomised controlled trial

BACKGROUND

Description of the condition

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and involves the progressive destruction of bone in the mandible or maxilla.

Osteonecrosis of the jaw (ONJ) associated with bisphosphonate treatment was first reported in 2003 (Marx 2003; Migliorati 2003; Ruggiero 2007; Sigua-Rodriguez 2014). Subsequently, ONJ was observed in individuals who took denosumab, an antiresorptive medication unrelated to the bisphosphonate class (Bone 2017). A growing number of case reports currently suggest that ONJ is also associated with antiangiogenic agents such as bevacizumab, aflibercept, sunitinib, temsirolimus, and everolimus (Ruggiero 2014; Zhang 2016). The condition formerly referred to as 'bisphosphonate-related ONJ' has been renamed 'medication-related ONJ' due to the growing number of ONJ cases associated with non-bisphosphonate treatments (Ruggiero 2014).

The exact mechanisms underlying MRONJ remain unknown. Interestingly, MRONJ is primarily limited to the maxillofacial region. In contrast to other skeletal bones, jaw bones (the alveolar process and periodontium) have relatively high vascularity, bone turnover, and remodelling because of continuous mechanical stress, which may make them vulnerable to the adverse effects of drugs. Proposed hypotheses that attempt to explain the localisation of MRONJ exclusively to the jaws include altered bone remodelling, angiogenesis inhibition, constant microtrauma, suppression of innate or acquired immunity, and possible effects of inflammation or infection (Ruggiero 2014).

According to the case definition provided by the American Society for Bone and Mineral Research and the American Association of Oral and Maxillofacial Surgeons, people may be considered to have MRONJ if all of the following characteristics are present: (i) current or previous treatment with antiresorptive or antiangiogenic agents, (ii) exposed or necrotic bone in the maxillofacial region that did not heal (by primary or secondary intent) within eight weeks after identification by a healthcare provider, (iii) no history of radiation therapy to the jaws, and (iv) no evidence of metastatic disease to the jaws (Ruggiero 2007; Sigua-Rodriguez 2014). MRONJ has been divided into four stages based on clinical symptoms. Stage 0 describes individuals with prodromal disease (unexposed variant). Bone exposure is common in individuals with stage 1 to 3 MRONJ without infection (stage 1), with infection (stage 2), or with infection as well as a pathological fracture or fistula, or evidence of osteolysis extending to the inferior border of the mandible or sinus floor (stage 3) (Table 1) (Ruggiero 2007; Ruggiero 2014; Sigua-Rodriguez 2014; Vescovi 2012a).

The frequency of MRONJ is highly variable and ranges from very rare (less than 1/10,000) to common (1/100 or more), depending on the drug, treatment indication (cancer versus osteoporosis), dose, and duration of treatment (Dodson 2015). For example, in randomised controlled trials (RCTs) and a meta-analysis the incidence of MRONJ in individuals with cancer exposed to IV zoledronic acid was between 0.3 and 5% (Coleman 2011; Lopez-Olivo 2012; Mauri 2009; Morgan 2010). The reported risk of MRONJ

in individuals with cancer treated with denosumab ranged from 0.7% to 1.9% (Boquete-Castro 2016; Qui 2014; Ruggiero 2014). A meta-analysis that compared the safety of denosumab and zoledronic acid in individuals with bone metastases did not reveal a significant difference in the risk of MRONJ between the denosumab and zoledronic acid groups (Chen 2016).

Among individuals with osteoporosis, who receive substantially lower doses of bisphosphonates or denosumab than those with cancer, MRONJ is rare and the incidence may not be substantially greater than the natural background incidence of the condition. In people receiving bisphosphonates to treat osteoporosis, incidence estimates range from less than 0.1 to 0.7 cases per 10,000 patient years of exposure (Chamizo Carmona 2013; Grbic 2010). In a recent report studying people exposed to denosumab for treatment of osteoporosis, the incidence of MRONJ was 5.2 per 10,000 patient-years (Bone 2017). The risk for MRONJ among people with osteoporosis treated with bisphosphonates or denosumab approximates the risk for MRONJ that is observed in placebo groups (Bone 2017; Grbic 2010). The risk of MRONJ among people exposed to antiresorptive medications for the treatment of osteoporosis is approximately 100-fold smaller than the risk in people with cancer (Ruggiero 2014).

Evidence supporting the association of antiangiogenic medications with the development of MRONJ is primarily based on case reports. The frequency of MRONJ in people receiving antiangiogenic agents is not known accurately and reliably. Analysis of the United States Food and Drug Administration's Adverse Event Reporting System database showed that the intravenous BPs were associated with the highest risk for MRONJ, denosumab was associated with risk comparable to bisphosphonates used for osteoporosis, and the antiangiogenic agents were associated with the lowest risk for MRONJ (Zhang 2016). In a combined analysis of three phase III trials the incidence of MRONJ in people exposed to the angiogenesis inhibitor bevacizumab was 0.2% (Guarneri 2010). The incidence was substantially higher in those exposed to both zoledronic acid and bevacizumab (Guarneri 2010).

The treatment of MRONJ is challenging, and an effective and appropriate therapy that substantially improves the outcome remains to be identified. The median time to resolution of osteonecrosis symptoms may be up to 12 months and depends on the specific therapeutic intervention (Hinson 2015). Additional information on the natural history of MRONJ comes from a report of individuals with multiple myeloma who were prospectively observed for a minimum of 3.2 years following diagnosis (Badros 2008). MRONJ resolved in 62% of cases, resolved and then recurred in 12%, and did not heal in 26%.

Antiresorptive medications associated with MRONJ

Bisphosphonates are osteotropic agents with antiresorptive activity that are used in a wide spectrum of indications such as the treatment and prevention of osteoporosis, as well as the treatment of Paget's disease, multiple myeloma, and malignancy-associated hypercalcaemia. Bisphosphonates bind to bone hydroxyapatite and specifically inhibit the activity of osteoclasts, the bone-resorbing cells. Bone turnover is thereby reduced, which results in an increase in the mineral density of the bone and a reduction in serum calcium (Chestnut 2001; Guyatt 2002; Ruggiero 2007; Sigua-Rodriguez 2014). Bisphosphonates have a long retention time in bone, and effects may persist for

some time after treatment has been stopped. There are two major risk categories for bisphosphonate-related ONJ: (i) low risk in individuals without cancer treated with oral bisphosphonates (e.g. alendronic acid, clodronic acid, etidronic acid, ibandronic acid, and risedronic acid) or intravenous bisphosphonates (e.g. ibandronic acid and zoledronic acid) for osteoporosis, Paget's disease, osteopenia, and osteogenesis imperfecta; and (ii) high risk in individuals with cancer treated with intravenous bisphosphonates (e.g. zoledronic acid, pamidronic acid, and ibandronic acid) for multiple myeloma and bone metastases (Bagan 2009; Ruggiero 2014; Vescovi 2012a). Additional parameters affecting the development of bisphosphonate-related ONJ include the duration of bisphosphonate exposure, age, comedication, comorbidity, smoking, and oral health/oral hygiene (Bamias 2005; Dimopoulos 2006; Katsarelis 2015; Ruggiero 2014; Sigua-Rodriguez 2014).

Denosumab, a potent antiresorptive agent, is used to treat osteoporosis in postmenopausal women and in men who have an increased risk of fracture. The recommended dose is 60 mg administered as a single subcutaneous injection once every 6 months. Denosumab is also used to prevent bone complications in adults with bone metastases from solid tumours and to treat a type of bone cancer called giant cell tumour of bone. The recommended maintenance dose for the latter indications is much higher, 120 mg every 4 weeks. Denosumab is a monoclonal antibody, which has been designed to attach to an antigen called RANK ligand (RANKL). By attaching to and blocking RANKL, denosumab reduces the formation and activity of osteoclasts, the cells in the body that are involved in breaking down bone tissue (Katsarelis 2015; Pageau 2009; Ruggiero 2014; Xu 2013). The exact pathophysiological mechanisms of denosumab-related ONJ are currently unknown.

Antiangiogenic medications associated with MRONJ

Antiangiogenic agents are increasingly used as anticancer drugs for the treatment of renal cell carcinomas, gastrointestinal tumours, and other solid tumours. The drugs interfere with the formation of new blood vessels by inhibiting angiogenesis signalling cascades, such as vascular endothelial growth factor signalling (bevacizumab and aflibercept), mechanistic target of rapamycin signalling (temsirolimus and everolimus), or receptor tyrosine kinase signalling (sunitinib). MRONJ is a known, rare side effect of these agents, possibly resulting from their interaction with wound healing or osteoclast differentiation and survival (Patel 2015; Ruggiero 2014). Drug approval authorities (US Food and Drug Administration, European Medicines Agency) have included drug safety warnings in the drug labels of bevacizumab, aflibercept, and sunitinib regarding the risk of MRONJ.

Description of the intervention

Interventions for the prevention of MRONJ in at-risk individuals or the management of MRONJ in individuals with manifest disease may include the following.

Prophylaxis of MRONJ

A range of dental prophylactic measures may be used alone or in combination. A primary means of prevention is the completion of all dental treatment (such as restorative therapy, root canal treatment, periodontitis therapy, or tooth extraction) before the commencement of antiresorptive or antiangiogenic therapy or as soon as possible following the commencement of antiresorptive or antiangiogenic therapy to ensure that treatment is completed

within the specified 'time frame' for the intended agent. Antibiotic prophylaxis or antiseptic mouthwash (e.g. chlorhexidine) may be used. Individuals may take part in a preventive recall programme, or be provided with information regarding antiresorptive or antiangiogenic therapy risks, professional teeth cleaning, effective oral hygiene, and the importance of limiting or ceasing oral health risk behaviours (such as smoking and drug and alcohol use), or both. Surgical interventions may use a non-traumatic surgical technique (i.e. surgical treatment designed to minimise tissue damage). The use of plasma rich in growth factors (PRGF) may promote bone and adjacent soft tissue regeneration in post-extraction defects, thereby reducing the risk of MRONJ. To minimise wound exposure to bacteria, reconstructive surgical techniques for wound closure can be used. Some specific dental extraction methods recommend the discontinuation of antiresorptive or antiangiogenic agents before dentoalveolar surgery.

Treatment of MRONJ

For individuals with established MRONJ, the objective is to control infection, minimise necrosis progression, and promote tissue healing (Bagan 2009; Rollason 2016; Ruggiero 2014; Sigua-Rodriguez 2014; Vescovi 2006; Vescovi 2012a). The standard medical care of MRONJ is currently anti-infective treatment with systemic antibiotics or oral antiseptic rinses (e.g. chlorhexidine), or both, and surgical debridement or resection (Ruggiero 2014).

Non-surgical treatment options

Healing may be stimulated by oral pentoxifylline and α -tocopherol (vitamin E) in addition to antimicrobial therapy. Other options are adjunct hyperbaric oxygen (HBO) therapy, which involves breathing pure oxygen in a pressurised room or tube, or topical ozone therapy (OT) to improve healing. Low-level laser therapy (LLLT) is also considered a promising adjunctive treatment method for MRONJ. The lasers most commonly used for biomodulation in bone are argon, carbon dioxide, helium/neon, and neodymium-doped yttrium-aluminium-garnet. The use of (autologous) platelet-rich plasma (PRP) has been suggested to enhance postsurgical wound healing. PRP is commonly used in a gel formulation, which is formed by mixing PRP (derived from the centrifugation of autologous whole blood) with thrombin and calcium chloride. PRP gel contains higher amounts of fibrinogen, platelets, and growth factors than whole blood. Moreover, bone may be restored by teriparatide, a recombinant form of parathyroid hormone. Teriparatide is approved for the treatment of osteoporosis but is used off-label for other indications such as fracture healing, dental stability, and ONJ. Recombinant human bone morphogenetic proteins (rhBMPs), which also have the ability to induce osteogenesis, are another treatment option to enhance bone healing in MRONJ. After sequestrectomy, a carrier/scaffold (absorbable collagen sponge) that contains rhBMP is placed into the defect.

Surgical treatment options

Surgical treatments include sequestrectomy, debridement, resection, immediate reconstruction. Surgical treatment may also include extraction of teeth within exposed necrotic bone.

How the intervention might work

Prophylaxis of MRONJ

Controlling risk factors for MRONJ may represent an effective prophylaxis for MRONJ. MRONJ is a complication that can develop spontaneously after dentoalveolar surgery in combination with antiresorptive agents. Therefore, the completion of necessary elective dentoalveolar surgery before the start of this therapy may help reduce the risk of MRONJ (Ruggiero 2007; Ruggiero 2014). Another known risk factor is infection (Katsarelis 2015; Ruggiero 2014). Dental prophylaxis, caries control, and conservative restorative dentistry are expected to minimise the number of bacteria and eliminate the ports of entry for bacteria, thereby reducing the risk of infection. Regular dental evaluations during antiresorptive or antiangiogenic therapy may help to recognise significant risks at an early stage and enable prompt measures to be taken to counter them (Ruggiero 2014; SDCEP 2017). If surgery is necessary, for example, during bisphosphonate therapy, wound exposure to bacteria may be controlled by antibiotic prophylaxis, antiseptic mouthwash, or both. Choosing of surgical procedures that help minimise bone exposure or trauma to the jaws may reduce the risk of MRONJ. Platelet-derived growth-factor preparations, such as PRP and PRGF, applied at the surgical site may accelerating wound healing and reduce the time of increased infection risk. Stopping antiresorptive drugs prior to an invasive dental procedure (drug holiday) could be useful for prevention of MRONJ. Due to the pharmacokinetics, the antiresorptive effect of bisphosphonates and denosumab is maintained for several weeks or months. This would require cessation of antiresorptive therapy for at least two months to significantly reduce the risk of MRONJ during invasive dental procedures (Ruggiero 2014; Damm 2013).

Treatment of MRONJ

Treatment objectives for people with a defined diagnosis of MRONJ are to control infection of the soft and hard tissues, and minimise the progression or occurrence of bone necrosis to optimise wound healing. Stage-dependent strategies to treat MRONJ have been proposed (Ruggiero 2014), which can be classified into non-surgical and surgical treatment.

Non-surgical treatment options

Non-surgical management includes, for example, drug treatment with teriparatide, which is a recombinant form of parathyroid hormone that stimulates osteoblasts to increase bone density when used intermittently. Alternative options are treatment with pentoxifylline and α -tocopherol in combination with antimicrobial therapy, OT, HBO, and LLLT (Vescovi 2012a). Pentoxifylline and α -tocopherol have been used to treat osteoradionecrosis for many years. Pentoxifylline, a methylxanthine derivative and phosphodiesterase inhibitor, improves blood flow by increasing erythrocyte flexibility and vasodilatation, and modulates immunological activity; α -tocopherol has antioxidant properties (Epstein 2010); pentoxifylline and α -tocopherol may play a role in encouraging wound healing and reducing scarring; ozone has antimicrobial and wound-healing properties, and OT as an adjunct treatment has been hypothesised to induce the repair of tissues by cleansing osteonecrotic lesions, which leads to mucosal healing (Petrucchi 2007; Ripamonti 2011). HBO has been shown to be effective in addition to conventional therapies to treat osteoradionecrosis (Bennett 2016). HBO has been proven to stimulate new blood vessel growth within the damaged tissues

and to improve the availability of oxygen for wound healing. Thus, HBO has been hypothesised to be a useful adjunctive treatment for MRONJ (Freiberger 2009). Phototherapy with a low-intensity laser is used as an adjunctive therapy for treating several diseases including wounds. The laser light used with LLLT lies within the red visible and near infrared wavelengths, promoting biological effects, such as inflammation and angiogenesis; it also increases the inorganic matrix, which may support wound healing (Martins 2012; Vescovi 2006). Platelet-derived growth-factor preparations, such as PRP and PRGF, are applied at the surgical site as an adjuvant to stimulate regeneration of osseous and epithelial tissues, thereby accelerating wound healing. Platelet-derived growth-factors are proposed to support angiogenesis and to improve bone formation by enhancing osteoblast formation and activity (Lee 2007; Lopez-Jornet 2016). rhBMP is used in surgical procedures to improve bone formation and remodelling during bone healing by enhancing the effects of osteoblast formation and activity (Gerard 2014).

Surgical treatment options

Surgical treatments may include a more conservative approach, such as sequestrectomy and surgical debridement or aggressive therapies, such as resections of affected bone with reconstruction. One of the advantages of using a more conservative surgical approach like sequestrectomy is that a better healing should be expected since the periosteum and unaffected bone are conserved (Eckardt 2011; Stanton 2009; Comas-Calonge 2017).

Why it is important to do this review

Cochrane Oral Health undertook an extensive prioritisation exercise in 2014 to identify a core portfolio of titles that were the most clinically important to maintain on the Cochrane Library (Worthington 2015). This review was identified as a new priority title by the oral and maxillofacial surgery expert panel (Cochrane Oral Health priority review portfolio).

Among the drugs associated with MRONJ, bisphosphonates are by far the most widely used for a wide range of clinical indications. For example, bisphosphonates can be used in breast cancer and prostate cancer, which have the highest sex-related incidence rates worldwide. Osteoporosis, another common indication for bisphosphonates, is estimated to affect 200 million women worldwide: approximately one-tenth of women aged 60 years, one-fifth of women aged 70 years, two-fifths of women aged 80 years, and two-thirds of women aged 90 years (Kanis 2007). Moreover, several other drugs (denosumab, antiangiogenic medications) have recently been associated with MRONJ. MRONJ may occur as a common side effect, particularly in individuals with cancer, depending on the drug and the dosage used. Therefore, the population at risk for MRONJ is large and expanding, and the public health implications may be substantial.

MRONJ significantly affects quality of life (QoL) and the decline in QoL correlates with MRONJ stage (Kyrgidis 2012; Miksad 2011). The following factors contribute to impairment of QoL: (i) infected and painful necrotic jaw bone; (ii) ulcerated, painful, and swollen oral mucosa; (iii) chronic sinus tracts and facial disfigurement; (iv) impaired speech, swallowing, and eating; and (v) frequent medical and dental evaluations and treatments (Migliorati 2010). Rehabilitation after a complete cure of MRONJ is often protracted. A further aggravating circumstance is a high risk of recurrence, which is higher than in other diseases of the jaw bone. Thus, it

is important to develop strategies to prevent or manage MRONJ. Preventative dentistry may be shown to decrease the incidence of MRONJ, in which case the implementation of preventive strategies will become an important consideration for individuals, clinicians, and policy makers (Dimopoulos 2006; Ripamonti 2009). Epidemiological studies have shown that the risk of MRONJ increases with a longer duration of treatment and with higher drug doses. Effective measures to prevent and treat MRONJ may significantly improve the risk-benefit balance, in particular for people requiring long-term or high-dose therapy.

However, there is uncertainty regarding how to prevent MRONJ before and during bisphosphonate therapy and how to manage manifest MRONJ (Lopez-Jornet 2010). As a consequence, current recommendations are contradictory in certain respects (Ruggiero 2014; SDCEP 2017). This review complements and extends the previous Cochrane review by Rollason 2016, which focused on interventions for treating ONJ associated with bisphosphonate drugs.

OBJECTIVES

To assess the effects of interventions versus no treatment, placebo, or an active control for the prophylaxis of MRONJ in people exposed to antiresorptive or antiangiogenic drugs.

To assess the effects of non-surgical or surgical interventions (either singly or in combination) versus no treatment, placebo, or an active control for the treatment of people with manifest MRONJ.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs) comparing one modality of intervention with another for the prevention or treatment of MRONJ. We excluded quasi-randomised and non-RCTs, as well as case studies, case series (or those of case series design), and cross-sectional studies. We did not exclude studies on the basis of language, publication status or date of publication.

Types of participants

To assess preventive strategies, we included participants who were treated with known risk medications and who had not yet developed MRONJ before assignment to the experimental or control group.

To assess interventions to treat MRONJ, we included people who had developed clinically apparent MRONJ. Case definition included exposure to risk drug and the presence of necrotic bone or fistulae that probes to bone.

We applied no restrictions regarding participant sex, age, initial health status, and pre-existing conditions, or type of ONJ-related drug (e.g. alendronic acid, clodronic acid, etidronic acid, ibandronic acid, incadronic acid, olpadronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid, denosumab, bevacizumab, aflibercept, sunitinib, temsirolimus, or everolimus), dose, or duration of therapy. To comply with the MRONJ case definition (Ruggiero 2014), we did not include participants with a history of head and neck radiation therapy.

Types of interventions

For prophylaxis of MRONJ

Any intervention (before or after commencement of antiresorptive or antiangiogenic drug therapy) that aims at prevention of MRONJ. Examples of interventions discussed in the literature include the following.

- Completion of all necessary dental treatment before the commencement of antiresorptive or antiangiogenic agents or as soon as possible following commencement of antiresorptive or antiangiogenic agents
- Antibiotic prophylaxis or antiseptic mouthwash
- Preventive recall programme and provision of information for patients
- Non-traumatic surgery (i.e. surgical treatment designed to minimise tissue damage), reconstructive techniques for wound closure to minimise wound exposure to bacteria, and specific dental extraction protocols
- Supportive measures to accelerate wound healing after surgery, such as platelet-rich plasma (PRP) and plasma rich in growth factors (PRGF)
- Cessation of therapy with antiresorptive or antiangiogenic agents ('drug holiday') before invasive dental procedures

For treatment of MRONJ

Any intervention (non-surgical, surgical, or a combination of both) that aims to treat clinically manifest MRONJ. Examples of interventions discussed in the literature include the following.

- Non-surgical
 - * Antiseptic mouthwashes
 - * Antibiotic and antifungal therapy
 - * Parathyroid hormone and teriparatide
 - * Pentoxifylline and α -tocopherol
 - * Ozone therapy (OT)
 - * Hyperbaric oxygen therapy (HBO)
 - * Laser therapy (low-level laser therapy (LLLT))
 - * Platelet-derived growth-factor preparations, such as PRP and PRGF
 - * Recombinant human bone morphogenetic proteins (rhBMPs)
- Surgical
 - * Surgical debridement, sequestrectomy
 - * Jaw bone resection
 - * Extraction of teeth within exposed necrotic bone

Comparisons: any single or combined experimental intervention versus control. The control arm consisted of participants receiving no treatment, placebo, or an active control (e.g. standard care).

Types of outcome measures

Primary outcomes

Prophylaxis of MRONJ

Incidence of MRONJ

Two related measures are often used to describe the incidence of MRONJ: incidence proportion (cumulative incidence) and incidence rate of MRONJ. As the incidence rate of MRONJ peaks

after two to four years of exposure to bisphosphonates or denosumab in individuals with cancer (Henry 2011; Nakamura 2015; Saad 2012), we had originally planned to include only trials with a follow-up period of at least three years for the primary outcome. However, we found that the three-year follow-up threshold was not applicable as a strict selection criterion for the following reasons: a large proportion of individuals with metastatic cancer (i.e. those most likely to be affected by MRONJ) may die before reaching a three-year follow-up. Moreover, follow-up periods were reported inconsistently between studies (mean follow-up versus range, follow-up period of the total study population versus that for each study arm separately, follow-up per protocol versus follow-up period as observed).

Treatment of MRONJ

Healing of MRONJ

There is no standardised scale for the assessment of MRONJ healing. Healing of MRONJ may be defined based on clinical examination, imaging findings, or both. Wound healing may be defined as absolute area healed per day, percentage of initial area healed per day, and advance of the wound margin towards the wound centre per day. Wound healing may also be defined as the time taken for mucosa to completely cover necrotic tissue and exposed bone ('cure period'). Number of participants with resolution of MRONJ (defined as mucosal healing with covering of the area of exposed bone) within a prespecified period of time (e.g. one year) may also be used to describe the healing of MRONJ. Follow-up time should be at least one year for this primary outcome.

Secondary outcomes

Prophylaxis of MRONJ

- Quality of life (QoL)
- Time-to-event
- Rate of complications and side effects of the intervention

Treatment of MRONJ

- QoL
- Recurrence
- Rate of complications and side effects of the intervention

For the outcome 'complications', if the intervention involved interruption/delay of antiresorptive or antiangiogenic treatments, progression of the underlying disease (e.g. fracture in osteoporosis or disease progression in cancer), these were considered to be complications of the intervention.

For QoL measures, we reported whether validated scales were used. Non-validated scales were not excluded a priori. QoL had to have been measured at baseline and at least once during follow-up.

Search methods for identification of studies

Cochrane Oral Health's Information Specialist conducted systematic searches in the following databases for RCTs. Due to the Cochrane Crowd Project, which aimed to identify all clinical trials on the Embase database and add them to CENTRAL, only recent months of the Embase database were searched. Please see the [Cochrane Oral Health website](#) for more information.

Electronic searches

Cochrane Oral Health's Information Specialist searched the following databases for relevant trials:

- Cochrane Oral Health's Trials Register (searched 23 November 2016) (see [Appendix 1](#));
- The Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10) in the Cochrane Library (searched 23 November 2016) (see [Appendix 2](#));
- MEDLINE Ovid (1946 to 23 November 2016) (see [Appendix 3](#));
- Embase Ovid (23 May 2016 to 23 November 2016) (see [Appendix 4](#)).

The subject strategies for databases were modelled on the search strategy designed for MEDLINE Ovid in [Appendix 3](#). This was combined with subject strategy adaptations of the Highly Sensitive Search Strategy designed by Cochrane for identifying RCTs (as described in the *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0, Box 6.4.c. (Lefebvre 2011)).

Searching other resources

The following trial registries were searched for ongoing studies:

- US National Institutes of Health Ongoing Trials Register ([ClinicalTrials.gov](#); searched 23 November 2016) (see [Appendix 5](#));
- World Health Organization International Clinical Trials Registry Platform ([apps.who.int/trialsearch](#); searched 23 November 2016) (see [Appendix 6](#)).

We asked experts in the field to help identify unpublished literature and searched the reference lists of potential clinical trials in an attempt to identify any study not found by the other searches.

We searched the reference lists of included studies and relevant systematic reviews for further studies.

We did not perform a separate search for adverse effects of interventions used, we considered adverse effects described in included studies only.

Data collection and analysis

Selection of studies

Two review authors (NB, HH) independently assessed the titles and abstracts of each paper identified by the review search strategy. We excluded only clearly irrelevant records at this stage. Following this, we obtained the full text of potentially relevant studies and assessed these for eligibility based on the inclusion criteria as outlined above. In the event that the two review authors could not reach a consensus, another review author (OZ) acted as arbiter. We maintained a detailed log of study eligibility and reasons for exclusion, and recorded these in '[Characteristics of excluded studies](#)' tables.

Data extraction and management

Two review authors (NB, HH) independently collected details from the included trials using a structured form. If necessary, a third review author (OZ) was consulted to resolve inconsistencies. We extracted the following details and entered them into

'Characteristics of included studies' tables in Review Manager 5 (RevMan 5) (RevMan 2014).

- Methods
 - * Trial design
 - * Duration of study
 - * Sample size calculation
 - * Country of origin
 - * Year of publication
 - * Language of the original publication
 - * Category (i.e. prophylaxis or treatment of MRONJ)
 - * Funding
 - * Registration in a public trials registry
- Participants
 - * Number of participants
 - * Age
 - * Sex
 - * Condition treated with antiresorptive or antiangiogenic agents
 - * Inclusion criteria
 - * Exclusion criteria
- Interventions (i.e. the type of intervention and procedural information)
- Outcomes
 - * Primary outcomes
 - * Secondary outcomes

We planned to contact study authors to ask for further information or clarification of their data if necessary.

Assessment of risk of bias in included studies

Two review authors (NB, HH) independently assessed the risk of bias in the included studies according to guidelines in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011).

We assessed the included trials for risk of bias (high, low, or unclear) in the following key domains:

- random sequence generation (allocation bias);
- allocation concealment (allocation bias);
- blinding of participants and personnel (performance bias);
- blinding of outcome assessors (detection bias);
- incomplete outcome data (attrition bias);
- selective reporting (reporting bias).

'Unclear' indicates either a lack of information or uncertainty over the potential for bias. We completed a 'Risk of bias' table for each study and presented the results graphically by study and by domain over all studies. If the risk of bias was not clear because of a lack of detail in the studies, we planned to contact the study authors to request further information.

We categorised overall risk of bias by outcome as shown in the table below.

Risk of bias	Interpretation	Within a study	Across studies
Low risk of bias	Plausible bias unlikely to seriously alter the results	Low risk of bias for all key domains	Most information is from studies at low risk of bias
Unclear risk of bias	Plausible bias that raises some doubt about the results	Unclear risk of bias for one or more key domains	Most information is from studies at low or unclear risk of bias
High risk of bias	Plausible bias that seriously weakens confidence in the results	High risk of bias for one or more key domains	The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of results

Measures of treatment effect

We used RevMan 5 (RevMan 2014) to perform the analyses.

For continuous data, we planned to calculate the mean differences and 95% confidence intervals (CI). We planned to report continuous outcomes as means and standard deviations. When studies used different instruments to measure the same construct, we planned to use the standardised difference in means in the analysis to combine the data.

For dichotomous outcomes, we calculated risk ratios (RR) along with 95% CI from cumulative incidence data. In cases of reported incidence rates, the rate ratio was the effect measure of choice.

To summarise time-to-event data, we planned to use methods of survival analysis and we planned to express the intervention effect as a hazard ratio, along with 95% CI.

Where insufficient information was reported to enable effect measures to be calculated, we provided a narrative report of the summary measures.

Unit of analysis issues

The individual participant was the unit of analysis.

If there was a choice of timepoints for a primary outcome, we selected the timepoint closest to 3 years for prophylaxis and 1 year for treatment. We avoided multiple testing of the effect at each of the timepoints.

Dealing with missing data

We attempted, where feasible, to contact authors from the primary studies to obtain missing data. We used the methods outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* to

estimate the missing standard error of the log rate ratio (Higgins 2011).

Assessment of heterogeneity

To identify and measure the statistical heterogeneity of the data, we planned to use the I^2 statistic (Higgins 2003). This value (percentage) defines the variability in effect estimates between studies that is beyond what would be expected by chance. The I^2 value can be categorised as not important (0% to 40%), moderate heterogeneity (30% to 60%), substantial heterogeneity (50% to 90%), and very substantial heterogeneity (75% to 100%) (Higgins 2003). We also planned to use graphical displays, such as Galbraith plots, if appropriate. Galbraith plots enable the display of several estimates of the same quantity having different standard errors; this is why they provide a useful way of checking for the presence of heterogeneity (Anzuers-Cabrera 2010; Copas 2009). Clinical diversity (i.e. variability in the participants, interventions, and outcomes studied) may contribute to statistical heterogeneity. If a sufficient number of studies was included, we planned to explore heterogeneity by conducting subgroup analyses. If there was substantial evidence for between-study heterogeneity, we planned to use a random-effects meta-analysis.

Assessment of reporting biases

If there had been sufficient studies, we would have assessed publication bias using methods based on a funnel plot, such as Egger's test (Egger 1997). However, all publication bias methods were characterised by a relatively low power and could not be assumed to prove or exclude publication bias (Higgins 2011).

Data synthesis

We followed the guidelines in the *Cochrane Handbook for Systematic Reviews of Interventions* for the statistical analysis of results (Higgins 2011). If the studies had been sufficiently similar with respect to the participants included, interventions compared, and outcomes and timepoints reported, we would have conducted meta-analyses. We would have used a random-effects or fixed-effect meta-analysis as appropriate to combine quantitative data. For comparisons in which a meta-analysis could not be carried out, we have provided a narrative report of the summary measures and treatment effects.

Subgroup analysis and investigation of heterogeneity

Clinical heterogeneity (i.e. differences associated with the participants, interventions, or outcomes across the included studies) may contribute to statistical heterogeneity (i.e. differences in the effects of interventions). If a sufficient number of studies were included, we planned to explore heterogeneity by conducting subgroup analyses in any case (i.e. whether statistical heterogeneity was present or not). To assess the effect of particular aspects of the studies on the primary and secondary outcome variables, we had planned to conduct the following subgroup analyses: medication dose or dose intensity (i.e. unit dose of medication administered per unit time); medication type (e.g.

nitrogenous or non-nitrogenous bisphosphonate) or compound; stage and type of disease (e.g. cancer or non-cancer); and risk factors (e.g. multimorbidity, age, smoker). If we had included at least 10 studies, we would have investigated these effects using a meta-regression analysis.

In the case of significant statistical heterogeneity, we would have attempted to identify the source of the heterogeneity with subgroup analyses.

Sensitivity analysis

If there had been sufficient RCTs for meta-analyses, we would have performed a sensitivity analysis to check the robustness of results when omitting studies with high or unclear risk of bias or to investigate whether the meta-analysis result was heavily determined by outlier studies. We would have used the Galbraith plot to detect potential outliers.

Presentation of main results

We have developed a 'Summary of findings' table for each comparison, and have presented summary information for the primary and secondary outcomes.

Following GRADE methods and using GRADEPro software (GRADEPro 2014), two review authors (NB and OZ) assessed the quality of evidence with reference to the overall risk of bias of the included studies, directness of the evidence, consistency of the results, precision of the estimates, and risk of publication bias. Factors that may lead to downgrading of evidence in the GRADE approach are: (a) risk of bias, (b) inconsistency between studies, (c) indirectness, (d) imprecision, and (e) likely publication bias. Factors that may lead to upgrading are: (a) large effect size, (b) dose-response gradient, (c) if all plausible confounding would reduce a demonstrated effect, and (d) if all plausible confounding would suggest a spurious effect when the actual results show no effect. We assessed the quality of the body of evidence for each comparison and outcome as high, moderate, low, or very low.

RESULTS

Description of studies

See [Characteristics of included studies](#); [Characteristics of excluded studies](#); [Characteristics of ongoing studies](#).

Results of the search

The search retrieved 1105 references after de-duplication. After screening the titles and abstracts, we excluded all but 23 references from further evaluation. We examined the full text of the remaining 23 articles and found that eight references relating to five studies met the prespecified inclusion criteria and were therefore included in this review. We identified four additional studies that are ongoing and listed these under [Characteristics of ongoing studies](#). We excluded 11 full-text articles for reasons noted in the [Characteristics of excluded studies](#) table. The flow diagram (Figure 1) displays the study selection process.

Figure 1. Study flow diagram. Results of the search strategy for inclusion of studies in this review

Included studies

We included five studies in this review (Freiberger 2012; Mozzati 2012; Mozzati 2013; Mücke 2016; Ristow 2016). For details, see the [Characteristics of included studies](#) table. Three studies focused on the prophylaxis of MRONJ (Mozzati 2012; Mozzati 2013; Mücke 2016). Two trials investigated options for the treatment of MRONJ (Freiberger 2012; Ristow 2016). The trials varied in sample size between 40 (Ristow 2016) and 700 participants (Mozzati 2013). In total, 1218 participants were included in this review. More women than men took part in the studies, with the exception of one study (Mücke 2016), which recruited only men with prostate cancer.

Prophylaxis of MRONJ

Mücke 2016 involved 253 men with prostate cancer and bone metastases who received treatment with intravenous zoledronic acid. This study was conducted at the University of Munich, Germany, from 2008 to 2014. All participants had baseline assessments and treatments, if necessary, before the start

of bisphosphonate therapy. Participants in the control group were monitored and treated when deemed necessary by the participant's dentist and were re-evaluated once per year. In the experimental group, the participants were closely monitored and treated when necessary at 12-week intervals. Thirty-six of 126 participants randomly allocated to the experimental group refused close monitoring and changed to the control group. The primary outcome was the incidence of MRONJ. The major diagnostic criterion of MRONJ was non-healing exposed bone in the mandible or maxilla for longer than eight weeks. The incidence of MRONJ was calculated as the incidence rate (i.e. the number of people developing MRONJ per patient-years) and incidence proportion (i.e. number of people developing MRONJ relative to the number people in the study group). Follow-up was at least two years in the control group and at least one year in the experimental group. The effect on QoL was not investigated. Time-to-event data were not provided.

[Mozzati 2012](#) included 176 individuals with cancer treated with intravenous bisphosphonates who underwent dental extractions. Participants recruited from January 2005 to December 2009 at the University of Torino, Italy, were randomly allocated to the experimental group treated with PRGF, which was inserted into the postextraction alveolus, or the control group without PRGF. All participants had a professional oral hygiene session one week before surgery and antibiotics for six days starting the evening before surgery. Surgical care included anaesthesia by alveolar nerve block, no intraligamentous or intrapapillary infiltrations, mucosal flap, and suturing to enable healing via primary intention. After surgery, the participants were monitored (at 3, 7, 14, 21, 30, 60, 90, and 120 days, and thereafter every 6 months) for clinical signs of MRONJ, such as pain, swelling, and non-healing exposed necrotic bone or fistulae, or both, with connection to the bone. Follow-up was between 24 and 60 months. The primary outcome was the development of MRONJ. Intraoperative complications and time-to-event were recorded. QoL was not investigated.

Another RCT by Mozzati et al. prospectively compared two surgical protocols with different degrees of invasiveness for tooth extraction in people undergoing treatment with oral bisphosphonates ([Mozzati 2013](#)). Conditions treated with bisphosphonates were osteoporosis, rheumatoid arthritis, and Paget's disease. A total of 700 participants recruited from January 2005 to April 2011 at the University of Torino, Italy, were randomly assigned to delicate surgery and wound closure by primary intention or non-traumatic avulsion and wound closure by secondary intention. In the first group, surgical extraction was carried out via an intrasulcular incision and mobilisation of a mucoperiosteal flap. In the second group, extraction was carried out without detachment of full-thickness flaps, and sockets were filled with absorbable haemostatic gelatin sponges. After surgery, participants were monitored (at 3, 7, 14, 21, 30, 60, and 90 days, and thereafter every 6 months) for clinical signs of MRONJ, such as pain, swelling, non-healing exposed necrotic bone or fistulae, or both, with connection to the bone. Follow-up was between 12 and 72 months. The primary outcome was the success rate, defined as the proportion of participants without clinical signs of postoperative MRONJ. Intraoperative complications were recorded. QoL was not investigated.

Treatment of MRONJ

[Freiberger 2012](#) tested HBO as an adjunct to routine surgery and antibiotics in the treatment of MRONJ caused by bisphosphonate use. A cohort size of 70 participants was planned for the study. From July 2006 to December 2010, the trial screened 133 people for eligibility, and 49 people with MRONJ were randomised to receive standard care with or without HBO. MRONJ in these people was related to the use of zoledronic acid, pamidronic acid, or alendronic acid for the treatment of multiple myeloma, breast cancer, osteoporosis, or other indications. Treatment for MRONJ included surgical debridement at the discretion of the referring surgeon and antibiotics for any sign of local infection. Participants in the HBO group received 40 HBO sessions at 2 atmospheres of pressure for 2 hours each over 4 weeks. The study participants had scheduled follow-up visits at 3, 6, 12, and 18 months, and

received 14 months of weekly status checks by telephone or email. Eighteen participants completed the full 24-month observation period. After randomisation, six participants changed from their allocated treatment arm to the alternative trial arm. For the primary outcome, oral lesions were scored by size and number, and a change in lesion scores compared with the baseline condition was used to grade the primary outcome. Possible outcome categories were healed (defined as gingival coverage with no exposed bone), improved, unchanged, or worse. Secondary outcomes were QoL (Duke Health Profile instrument), laboratory measures of bone turnover, and molecular indicators of osteoclast activation, such as RANK, RANKL, OPG, and pAKt. The rate of complications was not reported. The trial received financial support from the Novartis pharmaceutical company.

[Ristow 2016](#) compared autofluorescence-guided bone resection with tetracycline fluorescence-guided bone resection for the treatment of MRONJ. Forty participants suffering from MRONJ due to the use of antiresorptive medication (bisphosphonates with or without denosumab) for the treatment of cancer (85%) or osteoporosis (15%) were included. The major challenge in bone surgery in MRONJ is the delineation between necrotic and viable bone to ensure complete removal of necrotic bone while preserving as much vital bone as possible. In this open-label trial, 20 randomly assigned control participants received preoperative doxycycline, which is incorporated into viable bone and is visualised with a certified medical lamp intraoperatively. Twenty participants in the experimental group received ampicillin/sulbactam (or clindamycin 600 mg in case of hypersensitivity to penicillin or a penicillin allergy) preoperatively without doxycycline labelling. Autofluorescence of vital bone, which was induced with a special fluorescence lamp (provided for the study by the manufacturer), was used to visualise vital bone intraoperatively. The primary outcome was success rate, defined as the absence of a MRONJ site after surgery (i.e. full mucosal coverage at eight weeks after surgery). Secondary endpoints were mucosal integrity at the remaining measurement timepoints, loss of sensitivity (numbness) of the alveolar nerve (Vincent sign), subjective pain, and signs of infection. Participants were monitored at 10 days, 8 weeks, 6 months, and 1 year after surgery. QoL was not investigated. Rate of complications was not reported.

Excluded studies

After evaluation of the full-text articles, we excluded 11 studies because they were not RCTs ([Asaka 2016](#); [Bonacina 2011](#); [Bramati 2015](#); [Coviello 2012](#); [Dimopoulos 2009](#); [DE Iuliis 2014](#); [Lee 2014](#); [Montebugnoli 2007](#); [Pelaz 2014](#); [Vescovi 2010](#); [Vescovi 2012a](#)). Four studies are ongoing and study results are not yet available ([ACTRN12612000950864](#); [NCT01526915](#); [NCT02198001](#); [UMIN000009132](#)). See the [Characteristics of excluded studies](#) and [Characteristics of ongoing studies](#).

Risk of bias in included studies

See 'Risk of bias' in the included studies as a graphical overview in [Figure 2](#). See [Characteristics of included studies](#) tables for more details about our 'Risk of bias' assessments.

Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Freiberger 2012	?	+	-	-	-	+
Mozzati 2012	?	?	-	-	?	+
Mozzati 2013	+	?	-	-	?	+
Mücke 2016	?	?	-	-	-	+
Ristow 2016	?	?	-	-	+	+

Allocation

In all five trials, participants were randomly divided into two groups (Freiberger 2012; Mozzati 2012; Mozzati 2013; Mücke 2016; Ristow 2016). The authors of four trials did not mention the generation of randomisation sequence and we therefore rated the level of risk as unclear (Freiberger 2012; Mozzati 2012; Mücke 2016; Ristow 2016). The method of sequence generation was noted in only one study: the participants were assigned by a computer randomisation programme, and we judged the level of risk to be low (Mozzati 2013). Freiberger 2012 did not report the method of sequence generation but reported the concealment of allocation using a series of 70 opaque envelopes containing the assignment (judged as low risk). Allocation concealment was not reported for the other

studies, and we rated the risk level as unclear (Mozzati 2012; Mozzati 2013; Mücke 2016; Ristow 2016).

Blinding

Personnel were not blinded in all studies, either because of the nature of the intervention (Mozzati 2012; Mozzati 2013; Mücke 2016; Ristow 2016) or because blinding was deemed impractical (Freiberger 2012). Outcome assessors were not blinded in three studies (Freiberger 2012; Mücke 2016; Ristow 2016). Although not reported, masking of outcome assessors was most likely not present in the other two studies (Mozzati 2012; Mozzati 2013). Therefore, we considered the level of risk for performance and detection bias to be high for all studies.

Incomplete outcome data

We assessed the level of risk as unclear in two studies because completeness or loss to follow-up was not reported ([Mozzati 2012](#); [Mozzati 2013](#)).

We judged attrition bias to be high in [Freiberger 2012](#) and [Mücke 2016](#). Although a clear description of losses and withdrawals was given, data analysis was performed as-treated and not by intention-to-treat, and both studies had a high and unbalanced rate of crossovers between study arms. Neither study reported data in a format that would have enabled us to recalculate effects on an intent-to-treat basis.

In [Ristow 2016](#), some participants were lost for the assessment of secondary endpoints. However, no participants were lost for the assessment of the primary endpoint; hence, we rated attrition bias as low ([Ristow 2016](#)).

Selective reporting

Outcomes defined in the methods sections of the papers ([Freiberger 2012](#); [Mozzati 2012](#); [Mozzati 2013](#); [Mücke 2016](#); [Ristow 2016](#)) and the study protocol at ClinicalTrials.gov ([Freiberger 2012](#)) were completely reported with the exception of one study. [Freiberger 2012](#) did not report some predefined secondary outcomes, such as the results of serum measurements of bone turnover and molecular measures of osteoclast signalling. However, the authors stated that these results will be presented separately ([Freiberger 2012](#)). Altogether, we considered the risk of reporting bias to be low for all studies ([Freiberger 2012](#); [Mozzati 2012](#); [Mozzati 2013](#); [Mücke 2016](#); [Ristow 2016](#)).

Effects of interventions

See: [Summary of findings for the main comparison](#) Dental examinations at three-month intervals and preventive treatments (experimental) compared to standard care (control) for prophylaxis of MRONJ; [Summary of findings 2](#) A dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) compared to a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions; [Summary of findings 3](#) Hyperbaric oxygen therapy as an adjunct to conventional therapy (experimental) compared to conventional therapy (control) for treatment of MRONJ; [Summary of findings 4](#) Autofluorescence-guided bone surgery (experimental) compared to tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ

Prophylaxis of MRONJ

Regular dental examinations at three-month intervals and preventive treatments versus standard care for the prophylaxis of MRONJ in men with metastatic prostate cancer and intravenous zoledronic acid

We identified one study with 253 participants that explored the preventive effect of a prophylactic treatment to reduce MRONJ in men with metastatic prostate cancer treated with zoledronic acid ([Mücke 2016](#)). The study compared regular dental examinations at three-month intervals and preventive treatments (including antibiotics before dental extractions, and the use of techniques for wound closure that avoid exposure and contamination of bone)

versus standard care (i.e. monitoring and treatment if necessary at the discretion of the participant's dentist).

Incidence of MRONJ

Our primary outcome, incidence of MRONJ, was reported as incidence rate per year and incidence proportion. MRONJ was defined as the non-healing of exposed bone in the mandible or maxilla for longer than eight weeks without any change in the stage of disease. Mean follow-up time was 28.8 months. Regular dental examinations at three-month intervals and preventive treatments showed a lower risk ratio (RR) for MRONJ (0.10; 95% CI 0.02 to 0.39) compared to standard care when dental extractions were performed. There was also a significant difference in the number of MRONJ cases per patient-years (rate ratio 0.18; 95% CI 0.04 to 0.74). We rated the quality of the evidence for the primary outcome to be low. See [Summary of findings for the main comparison](#), [Analysis 1.1](#), and [Analysis 1.2](#).

Plasma rich in growth factors inserted into the postextraction alveolus in addition to standardised medical and surgical care versus standardised medical and surgical care alone for MRONJ prophylaxis in individuals treated with intravenous bisphosphonates who underwent dental extractions

One RCT reported the effect of PRGF for preventing MRONJ in 176 participants with cancer undergoing dental extractions ([Mozzati 2012](#)).

Incidence of MRONJ

The diagnosis of MRONJ was based on clinical examination and radiographic examinations. Clinical signs of MRONJ were pain, swelling, and non-healing exposed necrotic bone or fistulae, or both, with connection to the bone. The study group had a total follow-up period of 24 to 60 months. At the last contact, no participants in the PRGF group (N = 91) but five participants in the control group (N = 85) developed MRONJ. The RR was 0.08 (95% CI 0.00 to 1.51). We rated the quality of the evidence for the primary outcome to be very low. See [Summary of findings 2](#) and [Analysis 2.1](#).

Rate of complications and side effects of the intervention

No intraoperative complications were observed in either of the groups.

Delicate surgery and closure by primary intention versus non-traumatic tooth avulsion and closure by secondary intention for the prophylaxis of MRONJ in individuals treated with oral bisphosphonates who underwent dental extractions

One RCT with 700 participants compared wound closure by primary intention with wound closure by secondary intention after dental extractions in individuals treated with oral bisphosphonates ([Mozzati 2013](#)).

Incidence of MRONJ

The participants were regularly monitored for clinical signs of MRONJ: pain, swelling, and non-healing exposed necrotic bone or fistulae, or both, with connection to the bone. In both study arms, no case of postoperative MRONJ was observed.

Rate of complications and side effects of the intervention

No intraoperative complications were observed in either of the two groups.

Treatment of MRONJ

We identified two RCTs assessing the effect of different treatment protocols in people with manifest MRONJ ([Freiberger 2012](#); [Ristow 2016](#)).

Hyperbaric oxygen therapy in addition to standard care (antiseptic rinses, antibiotics, surgery) versus standard care

One RCT with 49 participants analysed the healing of MRONJ using HBO treatment in addition to standard care (antiseptic rinses, antibiotics, surgery) ([Freiberger 2012](#)). All participants terminated bisphosphonate administration before or at the time of consent, with the exception of one who continued bisphosphonate administration for one month after the initial examination.

Healing of MRONJ

Oral lesions were graded by size and number, and staged by clinical severity. The last contact was intended to be 24 months after consent; however, only 18 participants completed the full 24-month observation period. Healing was defined as gingival coverage with no exposed bone. HBO in addition to standard care did not significantly improve healing from MRONJ at any of the investigated timepoints (at last follow-up: RR 1.56; 95% CI 0.77 to 3.18). We rated the quality of the evidence for the primary outcome to be very low. See [Summary of findings 3](#) and [Analysis 3.1](#).

Quality of life

QoL was measured using the Duke Health Profile, a 17-question generic self-reporting instrument with six health domains (physical, mental, social, general, perceived health, and self-esteem) and four dysfunction measurements (anxiety, depression, pain, and disability) ([Freiberger 2012](#)). QoL assessments were recorded at the time of the initial interview and at six months. Only within-group comparisons for each domain were provided based on a dichotomous classification ('improved', 'no change, or worse'). Because no score values were provided, we were unable to make a between-group analysis.

Autofluorescence-guided bone surgery versus tetracycline fluorescence-guided bone surgery in individuals with MRONJ referred for surgical treatment

One RCT with 40 participants compared autofluorescence-guided and tetracycline fluorescence-guided bone surgery for the treatment of MRONJ ([Ristow 2016](#)).

Healing of MRONJ

The primary endpoint reported by [Ristow 2016](#) was success rate. Success was defined as the absence of a MRONJ site after surgery, specified as the maintenance of full mucosal coverage (mucosal integrity) after surgery at the time of the evaluation. All measurements were acquired at five specific timepoints: preoperatively, and 10 days, 8 weeks, 6 months, and 1 year after surgery. There was no significant difference between the autofluorescence- and the tetracycline fluorescence-guided groups at any of the timepoints (at one-year follow-up: RR 1.05; 95% CI 0.86 to 1.30). We rated the quality of the evidence for the primary outcome to be very low. See [Summary of findings 4](#) and [Analysis 4.1](#).

DISCUSSION

At present, the mechanisms of MRONJ are not well known, and the prevention and treatment of MRONJ remains challenging. Thus, it is important to identify effective strategies for managing this well-known complication of antiresorptive medication.

Summary of main results

We identified three randomised controlled trials (RCTs), each evaluating different interventions, for the prevention of MRONJ ([Mozzati 2012](#); [Mozzati 2013](#); [Mücke 2016](#)). There is low-quality evidence that dental examinations at three-month intervals and preventive treatments are more effective than standard care in reducing the incidence proportion and the incidence rate of MRONJ in individuals taking intravenous bisphosphonates for advanced cancer and bone metastases. After evaluation of the available evidence, it has not been possible to either claim or refute a benefit of PRGF, inserted into the postextraction alveolus during dental extractions, for the prevention of MRONJ. The available evidence was also insufficient to support either a more-invasive (delicate surgery and wound closure by primary intention) or less-invasive (non-traumatic avulsion and wound closure by secondary intention) surgical strategy for the prophylaxis of MRONJ after dental extractions. Two RCTs evaluating the effect of platelet-rich fibrin in the prevention of MRONJ after tooth extraction are ongoing ([NCT01526915](#); [NCT02198001](#)).

We identified two RCTs that evaluated specific methods to improve the healing of MRONJ, namely hyperbaric oxygen (HBO) therapy and fluorescence-guided bone surgery ([Freiberger 2012](#); [Ristow 2016](#)). There was insufficient evidence to either claim or refute a benefit of HBO as an adjunct to conventional therapy for improved healing of MRONJ. There was also insufficient evidence to support either auto-fluorescence-guided bone surgery or tetracycline fluorescence-guided bone surgery for improved healing of MRONJ. The small sample size may have contributed to a lack of measurable effect. Two ongoing trials are currently investigating teriparatide for the treatment of MRONJ ([ACTRN12612000950864](#); [UMIN000009132](#)).

Overall completeness and applicability of evidence

The types of interventions evaluated in the included RCTs varied widely and so we were not able to combine data from different studies.

The RCTs included only people with bisphosphonates for the treatment of cancer or osteoporosis, or both. Although one study allowed the participation of individuals treated with denosumab, no people treated with this antiresorptive medication were included ([Ristow 2016](#)). None of the trials investigated the association between MRONJ and antiangiogenic medications. Thus, the included RCTs do not cover the entire spectrum of medications associated with MRONJ.

One trial recruited a highly selective group of participants (i.e. men with prostate cancer receiving zoledronic acid for the treatment of bone metastases) ([Mücke 2016](#)). The applicability of the results of this study to other populations is unclear.

A subgroup of individuals, namely those with a history of head and neck radiation therapy, were generally excluded from the included trials due to the widely accepted case definition of MRONJ.

Although exclusion of these individuals may be useful in reducing the heterogeneity of the study populations and in controlling for an important influencing variable, this may have impaired the overall completeness of evidence.

Quality of the evidence

We judged the overall quality of the evidence to be low or very low, meaning that we are uncertain about the estimates of effect.

All included studies were assessed to have a high risk of bias overall, as they had at least one domain rated at high risk. All of the trials were open label. Due to their nature, some interventions could not be blinded to participants or surgeons. None of the trials blinded the outcome assessors. Altogether, a lack of blinding confers a high risk of bias. In one trial, the length of follow-up differed between comparison groups, which may have biased the results of the study (Mücke 2016). A high and unbalanced rate of crossovers after randomisation between the comparison groups in two trials may also have conferred a high risk of bias (Freiberger 2012; Mücke 2016). We also downgraded the quality of evidence due to imprecision (most studies included relatively few participants (Freiberger 2012; Ristow 2016) or had few events (Mozzati 2012; Mozzati 2013) and thus have wide 95% confidence intervals around the effect estimates).

Potential biases in the review process

The methods we used in the review were established and documented in advance of the review being undertaken. We were not influenced by prior knowledge of the study results when making judgements regarding study eligibility. We made no subsequent changes to the types of studies and types of participants to be included in the review as specified in the protocol, with one exception. For trials investigating the effects of interventions for the prophylaxis of MRONJ, we originally required a follow-up period of at least three years. The three-year follow-up threshold, however, turned out not to be a feasible selection criterion (see [Primary outcomes](#)). We consider this change to the inclusion criteria to be well justified, however, and we do not believe that we have introduced a relevant selection bias.

Cochrane Oral Health Information Specialist (Anne Littlewood) conducted comprehensive searches of journal and conference databases to ensure that all published and unpublished trials were identified. We did not limit the searches to a particular language. Two review authors independently extracted the trials that met the inclusion criteria. The study authors were contacted where necessary to ascertain if any newer data were available following publication.

Agreements and disagreements with other studies or reviews

Several systematic reviews addressing the prophylaxis and treatment of MRONJ have been published (Bermúdez-Bejarano 2017; Diniz-Freitas 2016; El-Rabbany 2017; Fliefel 2015; Khan 2015; Lopez-Jornet 2016; Rollason 2016; Rupel 2014; Silva 2016; Spanou 2015).

The most recent systematic review and meta-analysis on the effectiveness of treatments for MRONJ was conducted by El-Rabbany 2017. In their analysis, the review authors included non-RCTs and prospective cohort studies as well as RCTs. The review

concluded that surgical treatment is more effective than medical treatment for resolving MRONJ. The review authors admit that this conclusion was based on studies that had a medium-to-high risk of bias and low statistical power.

Another recent literature review focused on the role of antibiotics in the prophylaxis and treatment of MRONJ (Bermúdez-Bejarano 2017). The review included all types of trial designs including case series. Sparse clinical data and a lack of RCTs made it impossible to definitively identify the most appropriate modality for each of the clinical situations studied.

A systematic review by Diniz-Freitas 2016 focused on strategies to prevent MRONJ in people undergoing dental extractions. As no eligible RCTs were identified, the analysis was based on case series and cohort studies. No conclusive scientific evidence was available regarding the efficacy of MRONJ prevention strategies in people treated with antiresorptive or antiangiogenic drugs subjected to tooth extraction.

Interventions for treating specifically bisphosphonate-related ONJ were evaluated in a Cochrane Review by Rollason 2016. The review, which considered only RCTs, identified one trial. This trial was also included in our analysis and evaluated the effect of HBO therapy adjunct to standard care (Freiberger 2012). Unlike our review, Rollason 2016 investigated 'improvement of osteonecrosis' as another primary outcome in addition to 'healing of osteonecrosis'. Rollason 2016 found that participants in the HBO group improved more than the standard-care group at the three-month follow-up. We did not consider the outcome 'improvement' in our review for the following reason. The outcome 'improvement' is less well defined than the outcome 'healing'. Improvement of MRONJ may not be stable. Whether MRONJ has improved at a given time point may not correlate with the true effectiveness outcome, namely healing of MRONJ. Consistent with our findings, Rollason 2016 did not observe a clear difference between the HBO and control groups for the outcome 'healed'. The authors concluded that this single RCT could not confirm or refute the effectiveness of HBO therapy. The authors stated that there is a lack of evidence from RCTs to guide the treatment of bisphosphonate-related ONJ.

All these reviews agree that high-quality research is required before conclusive statements can be made regarding strategies for the prevention or treatment of MRONJ.

AUTHORS' CONCLUSIONS

Implications for practice

Prophylaxis of MRONJ

We identified three randomised controlled trials (RCTs) that evaluated various interventions for the prophylaxis of medication-related osteonecrosis of the jaw (MRONJ) (Mozzati 2012; Mozzati 2013; Mücke 2016). One open-label RCT provided low-quality evidence that dental examinations at three-month intervals and preventive treatments are more effective than standard care in reducing the incidence of MRONJ in individuals taking intravenous bisphosphonates for advanced cancer and bone metastases (Mücke 2016). Our conclusion from the study is that individuals receiving intravenous bisphosphonates for advanced cancer and bone metastases should be placed on a regular recall schedule. Recall visits should include a check of oral hygiene, periodontal diseases, cavities, and effective infection control. Of note, 29%

of participants randomly allocated to the experimental arm later declined to have frequent dental check-up visits (Mücke 2016). Given that the adherence rates observed in clinical trials generally exceed those observed in a real-life setting, the limited acceptance of a dental monitoring programme among such individuals may limit the success of this preventive intervention. Thus, the motivation of these individuals is very important. The applicability of the study results to populations other than individuals with cancer taking intravenous bisphosphonates is unclear.

Dentoalveolar surgery is considered a major risk factor for developing MRONJ (Ruggiero 2014). Accordingly, two RCTs evaluated interventions, namely the use of plasma rich in growth factors (PRGF) and specific surgical techniques of wound closure, which were proposed to reduce the incidence of MRONJ in individuals undergoing dental extractions (Mozzati 2012; Mozzati 2013). There was insufficient evidence to either claim or refute a benefit of any of the tested interventions for the prophylaxis of MRONJ. In both trials, the small sample size in relation to the event rate of MRONJ may have contributed to the lack of measurable effect. This prevents us from drawing definitive conclusions regarding, as well as clinical recommendations for, the use of PRGF or specific surgical techniques in the prophylaxis of MRONJ in at-risk individuals undergoing dental extractions.

Treatment of MRONJ

The review authors found two RCTs that compared regimens for treating MRONJ. These RCTs evaluated the effectiveness of hyperbaric oxygen (HBO) as an adjunct therapy and methods for the visualisation of necrotic bone during sequestrectomy (Freiberger 2012; Ristow 2016). There was insufficient evidence to either claim or refute a benefit of any of the tested interventions for the treatment of MRONJ. The small sample size may have contributed to a lack of measurable effect. Moreover, methodological constraints of the trials were associated with a high risk of bias, contributing to uncertainty about any estimates of effect.

Implications for research

Prophylaxis of MRONJ

Incidence rates for MRONJ depend on the specific drug, its dose, and the duration of treatment, and range from 0.004% to

6.7% (Ruggiero 2014). Thus, depending on the population under investigation and the specific at-risk drug therapy, studies may require several hundred to several thousand participants in order to provide sufficient statistical power to detect meaningful effects of preventive measures on the incidence of MRONJ. Although dentoalveolar surgery is considered a common predisposing event for developing MRONJ (Ruggiero 2014), well-designed RCTs are lacking to identify effective preventive strategies in individuals at risk undergoing dentoalveolar surgery. Importantly, the concept of 'a drug holiday' (stopping medication) in individuals receiving oral bisphosphonates or denosumab who require tooth extractions is a matter of debate and requires future research (Damm 2013; Ruggiero 2014).

Treatment of MRONJ

Future RCTs should address important practice-related research questions, namely the comparison of surgical versus non-surgical protocols or conservative versus aggressive surgical protocols for the stage-specific treatment of MRONJ. Moreover, the evaluation of add-on effects for adjunct treatments such as HBO, α -tocopherol, pentoxifylline, ozone therapy, or low-level laser therapy, is important. Blinding of participants and clinicians (surgeons) may not be possible because of the nature of most interventions, but efforts should be made to ensure the blinding of outcome assessors (data collectors), which is crucial to ensure unbiased outcome assessment. One important limitation of existing RCTs was the small sample size. The sample size of future trials should be appropriate to allow meaningful conclusions to be drawn. In order to deal with the rare event rates of MRONJ, future trials should preferably follow a multicentric design and include sufficient participating centres. This will facilitate reaching a large number of cases.

ACKNOWLEDGEMENTS

We thank the editorial team at Cochrane Oral Health, especially Martin McCabe, Anne Littlewood, Laura CI MacDonald, Helen Wakeford, Tanya Walsh, Helen Worthington, and Jo Weldon. We would like to acknowledge the external referees Professor Juliet Compston, Professor Thomas B Dodson, and Dr Athanassios Kyrgidis for their helpful feedback, and Jason Elliot-Smith for final copy editing of the protocol for this review.

REFERENCES

References to studies included in this review

Freiberger 2012 {published data only}

* Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. *Journal of Oral and Maxillofacial Surgery* 2012;**70**(7):1573-83. [DOI: [10.1016/j.joms.2012.04.001](#); PUBMED: 22698292]

NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007).

Mozzati 2012 {published data only}

* Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. *Oral Oncology* 2012;**48**(9):817-21. [DOI: [10.1016/j.oraloncology.2012.03.009](#); PUBMED: 22483860]

Mozzati M, Arata V, Gallesio G, Carossa S. A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. *Joint, Bone, Spine* 2011;**78**(6):648-9. [DOI: [10.1016/j.jbspin.2011.04.017](#); PUBMED: 21703903]

Mozzati 2013 {published data only}

* Mozzati M, Arata V, Gallesio G. Tooth extraction in osteoporotic patients taking oral bisphosphonates. *Osteoporosis International* 2013;**24**(5):1707-1. [DOI: [10.1007/s00198-012-2239-8](#); PUBMED: 23288026]

Mozzati M, Arata V, Gallesio G, Carossa S. Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. *Joint, Bone, Spine* 2011;**78**(6):647-8. [DOI: [10.1016/j.jbspin.2011.04.018](#); PUBMED: 21703902]

Mücke 2016 {published data only}

* Mücke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years. *Journal of Cranio-maxillo-facial Surgery* 2016;**44**(10):1689-93. [DOI: [10.1016/j.jcms.2016.07.026](#); 27555374]

Ristow 2016 {published data only}

* Ristow O, Otto S, Geiß C, Kehl V, Berger M, Troeltzsch M, et al. Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. *International Journal of Oral and Maxillofacial Surgery* 2017;**46**(2):157-66. [DOI: [10.1016/j.ijom.2016.10.008](#); PUBMED: 27856150]

References to studies excluded from this review

Asaka 2016 {published data only}

Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrin may reduce the risk of delayed recovery

in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. *Clinical Oral Investigations* 2016 Nov 11 [Epub ahead of print]. [DOI: [10.1007/s00784-016-2004-z](#)]

Bonacina 2011 {published data only}

Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. *Journal (Canadian Dental Association)* 2011;**77**:b147.

Bramati 2015 {published data only}

Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. *Journal of Bone and Mineral Metabolism* 2015;**33**(1):119-24.

Coviello 2012 {published data only}

Coviello V, Peluso F, Dehkhargani SZ, Verdugo F, Raffaelli L, Manicone PF, et al. Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associated osteonecrosis of the jaw patients. *Journal of Biological Regulators and Homeostatic Agents* 2012;**26**(1):151-5.

DE Iuliis 2014 {published data only}

DE Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, et al. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. *Anticancer Research* 2014;**34**(5):2477-80.

Dimopoulos 2009 {published data only}

Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. *Annals of Oncology* 2009;**20**(1):117-20.

Lee 2014 {published data only}

Lee LW, Hsiao SH, Chen LK. Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. *Journal of the Formosan Medical Association* 2014;**113**(3):166-72.

Montebugnoli 2007 {published data only}

Montebugnoli L, Felicetti L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, et al. Bisphosphonate-associated osteonecrosis can be controlled by nonsurgical management. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics* 2007;**104**(4):473-7.

Pelaz 2014 {published data only}

Pelaz A, Junquera L, Gallego L, García-Consuegra L, Junquera S, Gómez C. Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: apilot study comparing fibrin rich in growth factors and teriparatide. *Medicina Oral, Patología Oral y Cirugía Bucal* 2014;**19**(4):e320-6.

Vescovi 2010 {published data only}

Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, et al. Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). *Lasers in Medical Science* 2010;**25**(1):101–13.

Vescovi 2012 {published data only}

Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S. Surgical approach and laser applications in BRONJ osteoporotic and cancer patients. *Journal of Osteoporosis* 2012;**2012**:Article ID 585434, 8 pages. [DOI: [10.1155/2012/585434](https://doi.org/10.1155/2012/585434)]

References to ongoing studies

ACTRN12612000950864 {unpublished data only}

ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw in patients treated with either bisphosphonates or denosumab? A randomised, controlled trial.. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=362988 (first received 9 September 2012).

NCT01526915 {unpublished data only}

NCT01526915. Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteonecrosis Provoked by Bisphosphonates (OCN/PRF). clinicaltrials.gov/ct2/show/record/NCT01526915 (first received 31 January 2012).

NCT02198001 {unpublished data only}

NCT02198001. Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction (PRF). clinicaltrials.gov/ct2/show/record/NCT02198001 (first received 15 July 2014).

UMIN000009132 {unpublished data only}

UMIN000009132. Study to the effect of teriparatide formulation Forteo versus Teribon on bisphosphonate-related osteonecrosis of the jaw in osteoporosis patients. upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000010706&language=E (first received 17 October 2012).

Additional references

Anzures-Cabrera 2010

Anzures-Cabrera J, Higgins JP. Graphical displays for meta-analysis: an overview with suggestions for practice. *Research Synthesis Methods* 2010;**1**(1):66–80. [DOI: [10.1002/jrsm.6](https://doi.org/10.1002/jrsm.6); PUBMED: 26056093]

Badros 2008

Badros A, Terpos E, Katodritou E, Goloubeva O, Kastiris E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. *Journal of Clinical Oncology* 2008;**26**(36):5904–9. [DOI: [10.1200/JCO.2008.16.9300](https://doi.org/10.1200/JCO.2008.16.9300); PUBMED: 19018084]

Bagan 2009

Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ). A concise update. *Oral Oncology* 2009;**45**(7):551–4.

Bamias 2005

Bamias A, Kastiris E, Bamia C, Mouloupoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. *Journal of Clinical Oncology* 2005;**23**(34):8580–7.

Bennett 2016

Bennett MH, Feldmeier J, Hampson NB, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. *Cochrane Database of Systematic Reviews* 2016, Issue 4. [DOI: [10.1002/14651858.CD005005.pub4](https://doi.org/10.1002/14651858.CD005005.pub4); PUBMED: 27123955]

Bermúdez-Bejarano 2017

Bermúdez-Bejarano EB, Serrera-Figallo MÁ, Gutiérrez-Corrales A, Romero-Ruiz MM, Castillo-de-Oyagüe R, Gutiérrez-Pérez JL, et al. Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates. *Journal of Clinical and Experimental Dentsitry* 2017;**9**(1):e141–9.

Bone 2017

Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. *The lancet. Diabetes & endocrinology* 2017;**5**(7):513–23. [DOI: [10.1016/S2213-8587\(17\)30138-9](https://doi.org/10.1016/S2213-8587(17)30138-9); PUBMED: 28546097]

Boquete-Castro 2016

Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. *Clinical Oral Implants Research* 2016;**27**(3):367–75. [DOI: [10.1111/clr.12556](https://doi.org/10.1111/clr.12556); PUBMED: 25639776]

Chamizo Carmona 2013

Chamizo Carmona E, Gallego Flores A, Loza Santamaría E, Herrero Olea A, Rosario Lozano MP. Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis. *Reumatología clínica* 2013;**9**(3):172–7. [DOI: [10.1016/j.reuma.2012.05.005](https://doi.org/10.1016/j.reuma.2012.05.005); PUBMED: 22784630]

Chen 2016

Chen F, Pu F. Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-Analysis of randomized controlled trials. *Oncology Research and Treatment* 2016;**39**(7-8):453–9. [DOI: [10.1159/000447372](https://doi.org/10.1159/000447372); PUBMED: 27487236]

Chestnut 2001

Chestnut C, Majumdar S, Gardner J. Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. *Advances in Experimental Medicine and Biology* 2001;**496**:95–7.

Coleman 2011

Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. *Breast Cancer Research and Treatment* 2011;**127**(2):429-38. [DOI: [10.1007/s10549-011-1429-y](https://doi.org/10.1007/s10549-011-1429-y); PUBMED: 21394500]

Comas-Calonge 2017

Comas-Calonge A, Figueiredo R, Gay-Escoda C. Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review. *Journal of clinical and experimental dentistry* 2017;**9**(2):e302-e307. [DOI: [10.4317/jced.53504](https://doi.org/10.4317/jced.53504); PUBMED: 28210453]

Copas 2009

Copas J, Lozada-Can C. The radial plot in meta-analysis: approximations and applications. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 2009;**58**(3):329-44. [DOI: [10.1111/j.1467-9876.2008.00650.x](https://doi.org/10.1111/j.1467-9876.2008.00650.x)]

Damm 2013

Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. *General Dentistry* 2013;**61**(5):33-8. [PUBMED: 23928436]

Dimopoulos 2006

Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Mouloupoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. *Haematologica* 2006;**91**(7):968-71.

Diniz-Freitas 2016

Diniz-Freitas M, Limeres J. Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review. *Medicina Oral, Patologia Oral y Cirugia Bucal* 2016;**21**(2):e250-9.

Dodson 2015

Dodson TB. The frequency of medication-related osteonecrosis of the jaw and its associated risk factors. *Oral and Maxillofacial Surgery Clinics of North America* 2015;**27**(4):509-16. [DOI: [10.1016/j.coms.2015.06.003](https://doi.org/10.1016/j.coms.2015.06.003); PUBMED: 26362367]

Eckardt 2011

Eckardt AM, Lemound D, Rana M, Gellrich N-C. Surgical Management of Bisphosphonate-related Osteonecrosis of the Jaw in Oncologic Patients: A Challenging Problem. *Anticancer Research* 2011;**31**:2313-2318.

Egger 1997

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *British Medical Journal* 1997;**315**(7109):629-34.

El-Rabbany 2017

El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication-related

osteonecrosis of the jaw: a systematic review and meta-analysis. *The Journal of the American Dental Association* 2017;**148**(8):584-94.e2.

Epstein 2010

Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology* 2010;**110**(5):593-6.

Fliefel 2015

Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. *International Journal of Oral Maxillofacial Surgery* 2015;**44**(5):568-85.

Freiberger 2009

Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. *Journal of Oral and Maxillofacial Surgery* 2009;**67**(5 Suppl):96-106.

Gerard 2014

Gerard DA, Carlson ER, Gotcher JE, et al. Early Inhibitory Effects of Zoledronic Acid in Tooth Extraction Sockets in Dogs Are Negated by Recombinant Human Bone Morphogenetic Protein. *J Oral Maxillofac Surg* 2014;**72**:61.

GRADEPro 2014 [Computer program]

GRADE Working Group, McMaster University. GRADEpro. Version 3.6. Hamilton (ON): GRADE Working Group, McMaster University, 2014.

Grbic 2010

Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. *The Journal of the American Dental Association* 2010;**141**(11):1365-70. [PUBMED: 21037195]

Guarneri 2010

Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. *Breast cancer research and treatment* 2010;**122**(1):181-8. [DOI: [10.1007/s10549-010-0866-3](https://doi.org/10.1007/s10549-010-0866-3); PUBMED: 20361252]

Guyatt 2002

Guyatt GH, Cranney A, Griffith L. Summary of meta-analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. *Endocrinology Metabolism Clinics of North America* 2002;**31**(3):659-79.

Henry 2011

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in

patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *Journal of Clinical Oncology* 2011;**29**(9):1125-32. [DOI: [10.1200/JCO.2010.31.3304](https://doi.org/10.1200/JCO.2010.31.3304); Pubmed: 21343556]

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

Higgins 2011

Higgins JP, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Hinson 2015

Hinson AM, Siegel ER, Stack BC Jr. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis. *Journal of Oral and Maxillofacial Surgery* 2015;**73**(1):53-62. [DOI: [10.1016/j.joms.2014.07.012](https://doi.org/10.1016/j.joms.2014.07.012); PUBMED: 25511956]

Kanis 2007

Kanis JA. Assessment of osteoporosis at the primary health-care level. Technical Report. Vol. **66**. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK, 2007.

Katsarelis 2015

Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. *Journal of Dental Research* 2015;**94**(4):534-9.

Khan 2015

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *Journal of Bone and Mineral Research* 2015;**30**(1):3-23.

Kyrgidis 2012

Kyrgidis A, Triaridis S, Kontos K, Patrikidou A, Andreadis C, Constantinidis J, et al. Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires. *Anticancer Research* 2012;**32**(8):3527-34. [PUBMED: 22843941]

Lee 2007

Lee CY, David T, Nishime M. Use of platelet-rich plasma in the management of oral bisphosphonate-associated osteonecrosis of the jaw: a report of 2 cases. *J Oral Implants* 2007;**33**:371.

Lefebvre 2011

Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Lopez-Jornet 2010

Lopez-Jornet P, Camacho-Alonso F, Molina-Minano F, Gomez-Garcia F. Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. *Journal of Evaluation in Clinical Practice* 2010;**16**(5):878-82.

Lopez-Jornet 2016

Lopez-Jornet P, Perez AS, Arturo SP, Rui AM, Aurelio T. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. *Journal of Cranio-maxillo-facial Surgery* 2016;**44**(8):1067-72.

Lopez-Olivo 2012

Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. *Supportive Care in Cancer* 2012;**20**(11):2985-98. [DOI: [10.1007/s00520-012-1563-z](https://doi.org/10.1007/s00520-012-1563-z); PUBMED: 22956190]

Martins 2012

Martins MA, Martins MD, Lascala CA, Curi MM, Migliorati CA, Tenis CA, et al. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. *Oral Oncology* 2012;**48**(1):79-84.

Marx 2003

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *Journal of Oral and Maxillofacial Surgery* 2003;**61**(9):1115-7. [PUBMED: 12966493]

Mauri 2009

Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. *Breast Cancer Research and Treatment* 2009;**116**(3):433-9. [DOI: [10.1007/s10549-009-0432-z](https://doi.org/10.1007/s10549-009-0432-z); PUBMED: 19521766]

Migliorati 2003

Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. *Journal of Clinical Oncology* 2003;**21**(22):4253-4. [DOI: [10.1200/JCO.2003.99.132](https://doi.org/10.1200/JCO.2003.99.132); PUBMED: 14615459]

Migliorati 2010

Migliorati CA, Mattos K, Palazzolo MJ. How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. *The Journal of the American Dental Association* 2010;**141**(5):562-6.

Miksad 2011

Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. *The Oncologist* 2011;**16**(1):121-32. [DOI: [10.1634/theoncologist.2010-0183](https://doi.org/10.1634/theoncologist.2010-0183); PUBMED: 21212433]

Morgan 2010

Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet* 2010;**376**(9757):1989-99. [DOI: [10.1016/S0140-6736\(10\)62051-X](https://doi.org/10.1016/S0140-6736(10)62051-X); PUBMED: 21131037]

Nakamura 2015

Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, et al. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. *Journal of Pharmaceutical Health Care and Sciences* 2015;**22**(1):34. [DOI: [10.1186/s40780-015-0035-2](https://doi.org/10.1186/s40780-015-0035-2); PUBMED: 26819745]

Pageau 2009

Pageau SC. Denosumab. *mAbs* 2009;**1**(3):210-5.

Patel 2015

Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. *British Dental Journal* 2015;**219**(5):203-7.

Petrucchi 2007

Petrucchi MT, Gallucci C, Agrillo A, Mustazza MC, Foà R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. *Haematologica* 2007;**92**(9):1289-90.

Qui 2014

Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. *International Journal of Clinical Oncology* 2014;**19**(2):403-10. [DOI: [10.1007/s10147-013-0561-6](https://doi.org/10.1007/s10147-013-0561-6); PUBMED: 23605142]

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Ripamonti 2009

Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. *Annals of Oncology* 2009;**20**(1):137-45. [PUBMED: 18647964]

Ripamonti 2011

Ripamonti CI, Cislighi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O₃) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I-II study. *Oral Oncology* 2011;**47**(3):185-90.

Rollason 2016

Rollason V, Laverrière A, MacDonald LCI, Walsh T, Tramèr MR, Vogt-Ferrier NB. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). *Cochrane Database of Systematic Reviews* 2016, Issue 2. [DOI: [10.1002/14651858.CD008455.pub2](https://doi.org/10.1002/14651858.CD008455.pub2)]

Ruggiero 2007

Ruggiero SL. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). *Clinical Cases in Mineral and Bone Metabolism* 2007;**4**(1):37-42. [DOI: [10.1016/j.joms.2014.04.031](https://doi.org/10.1016/j.joms.2014.04.031); PUBMED: 25234529]

Ruggiero 2014

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. *Journal of Oral and Maxillofacial Surgery* 2014;**72**(10):1938-56. [PUBMED: 25683041]

Rupel 2014

Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). *Oral Oncology* 2014;**50**(11):1049-57.

Saad 2012

Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Annals of Oncology* 2012;**23**(5):1341-7. [DOI: [10.1093/annonc/mdr435](https://doi.org/10.1093/annonc/mdr435); PUBMED: 21986094]

SDCEP 2017

Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw. Dundee, UK: SDCEP, 2017. <http://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/> (accessed 30 September 2017).

Sigua-Rodriguez 2014

Sigua-Rodriguez EA, da Costa Ribeiro R, de Brito AC, Alvarez-Pinzon N, de Albergaria-Barbosa JR. Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. *International Journal of Dentistry* 2014;**2014**:192320. [PUBMED: 24868206]

Silva 2016

Silva LF, Curra C, Munerato MS, Deantoni CC, Matsumoto MA, Cardoso CL, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review. *Oral and Maxillofacial Surgery* 2016;**20**(1):1-17.

Spanou 2015

Spanou A, Lyritis GP, Chronopoulos E, Tournis S. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review. *Oral Diseases* 2015;**21**(8):927-36.

Stanton 2009

Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review

of 33 surgical cases. *Journal of Oral and Maxillofacial Surgery* 2009;**67**:943-50.

Vescovi 2006

Vescovi P, Merigo E, Meleti M, Manfredi M. Bisphosphonate-associated osteonecrosis (BON) of the jaws: a possible treatment?. *Journal of Oral and Maxillofacial Surgery* 2006;**64**(9):1460-2.

Vescovi 2012a

Vescovi P. Bisphosphonates and osteonecrosis: an open matter. *Clinical Cases in Mineral and Bone Metabolism* 2012;**9**(3):142-4. [PUBMED: 23289026]

Worthington 2015

Worthington H, Clarkson J, Weldon J. Priority oral health research identification for clinical decision-making. *Evidence-Based Dentistry* 2015;**16**(3):69-71. [PUBMED: 26492797]

Xu 2013

Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone—a review and future management considerations. *Current Oncology* 2013;**20**(5):e442-7.

Zhang 2016

Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langae TY, et al. Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). *Journal of Bone and Mineral Research* 2010;**31**(2):336-40. [DOI: [10.1002/jbmr.2693](https://doi.org/10.1002/jbmr.2693); PUBMED: 26288087]

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Freiberger 2012

Methods	<ul style="list-style-type: none"> • Trial design: single-centre, interventional, prospective, unblinded, randomised controlled trial • Duration of study: enrolment period from July 2006 to December 2010 • Follow-up: per protocol 2 years • Sample size calculation: quote: "The target study sample size was calculated based on the primary outcome variable (change in oral lesion size and number) and indicated a requirement for 33 to 37 subjects with MRONJ per group. This assumed a spontaneous remission rate of 5% to 10% for the study to detect at least a 25% difference in cure rates between HBO-treated patients and non-treated controls. The authors used a value equal to 0.05 and a power equal to 0.80 for these calculations." • Country of origin: USA • Year of publication: 2012 • Language of the original publication: English • Category: treatment of MRONJ, non-surgical • Funding: quote: "This work was supported by a grant from Novartis Healthcare." • Registration in a public trials registry: NCT00462098
Participants	<ul style="list-style-type: none"> • 49 participants with MRONJ randomised into 2 groups: 27 control (standard care), 22 experimental (standard care + hyperbaric oxygen [HBO]) • Mean age: control 66 yr, HBO 66 yr • Sex: control 56% female, HBO 59% female • Condition treated with bisphosphonates: osteoporosis (15% of total sample), cancer and other indications (85% of total sample) • Inclusion criteria: <ul style="list-style-type: none"> • * Able to consent • * Has taken bisphosphonates • * Presence of exposed bone in the maxillofacial area with no evidence of healing after 6 weeks of appropriate evaluation and dental care • * no radiation history of the affected area • Exclusion criteria: <ul style="list-style-type: none"> • Unable to consent • Ineligible for HBO • Taking protease inhibitors for HIV • Any past history of radiation to the jaw

Freiberger 2012 (Continued)

- Metastatic or recurrent malignant disease of the jaw or oropharynx
- Life expectancy less than 12 months
- Tobacco use
- Pregnancy

Interventions	<ul style="list-style-type: none"> • Control: standard care (antiseptic rinses, antibiotics, and surgery, if indicated by the participant's individual conditions) • Experimental: standard care plus 40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each, twice a day
Outcomes	<ul style="list-style-type: none"> • Primary: <ul style="list-style-type: none"> • * Change from baseline in oral lesion size and number • Secondary: <ul style="list-style-type: none"> • Pain (0- to 10-point Likert scale) • Quality of life (Duke Health Profile, a 17-question generic self-reporting instrument) • Serum measurements of bone turnover (data collected but not reported) • Molecular measures of osteoclast signalling (data collected but not reported)

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of sequence generation not reported
Allocation concealment (selection bias)	Low risk	Quote: "The randomization of patients with MRONJ to treatment groups was performed after informed consent, but before the initial staging examination using a series of 70 opaque envelopes containing the assignment."
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "The subjects and staff were not blinded to therapy because of the impracticality of providing sham HBO; however, the oral-maxillofacial surgeon was not told the subjects' assignments before the initial staging examination."
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "Lesion scores at the time of last contact were assigned by the study team, including the oral-maxillofacial surgeon." No blinding of outcome assessment
Incomplete outcome data (attrition bias) All outcomes	High risk	High attrition rate: at the 12- and 18-month evaluations 50% and 63%, respectively, of participants were lost to follow-up. High and unbalanced rate of crossovers: after randomization 5 participants switched from the control to the HBO group; 1 participant assigned to the HBO group declined HBO treatment and was switched to the control group. Data analysis: as-treated, not by intention-to-treat
Selective reporting (reporting bias)	Low risk	Serum measurements of bone turnover and molecular measures of osteoclast signalling were not reported. These are not primary outcomes and will be "reported separately". All other outcome variables listed in the Methods and the study protocol were reported.

Mozzati 2012

Methods	<ul style="list-style-type: none"> • Trial design: single-centre, interventional, prospective, unblinded, randomised controlled trial • Duration of study: January 2005 to December 2009 • Follow-up: between 24 and 60 months • Sample size calculation: not provided • Country of origin: Italy • Year of publication: 2012 • Language of the original publication: English • Category: prophylaxis of MRONJ • Funding: not reported • Registration in a public trials registry: not reported
Participants	<ul style="list-style-type: none"> • 176 participants randomised into 2 groups: 85 control, 91 experimental (plasma rich in growth factors [PRGF]) • Age 44-60 yr: control 27, PRGF 22 • Age 60-70 yr: control 36, PRGF 43 • Age 70-83 yr: control 22, PRGF 26 • Sex: control 54% female, PRGF 60% female • Condition treated with intravenous (IV) bisphosphonate (zoledronic acid): breast cancer, prostate cancer, ovarian cancer, lung cancer, and multiple myeloma • Inclusion criteria: <ul style="list-style-type: none"> * Current IV bisphosphonate therapy * The necessity for removal of strongly compromised dental elements • Exclusion criteria <ul style="list-style-type: none"> * Any previous history of irradiation to the maxillofacial area * Dental extractions before the study period
Interventions	<ul style="list-style-type: none"> • Control: standardised medical (professional oral hygiene session 1 week before surgery; antibiotics for 6 days starting the evening before surgery) and surgical care (anaesthesia by alveolar nerve block, no intraligamentous or intrapapillary infiltrations; mucosal flap and suturing to enable healing via primary intention) • Experimental: standardised medical and surgical care plus PRGF fraction inserted into the postextraction alveolus
Outcomes	<ul style="list-style-type: none"> • Postoperative bisphosphonate-associated osteonecrosis <p>Follow-up examinations: mucosal healing was monitored at 3, 7, and 14 days postoperatively; monitoring for MRONJ was continued at 21, 30, 60, 90, and 120 days, and 6 months, followed by visits every 6 months</p>
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "The study cohort was divided randomly into two groups of 50 subjects" Generation of randomisation sequence not reported
Allocation concealment (selection bias)	Unclear risk	Concealment of allocation not reported
Blinding of participants and personnel (performance bias)	High risk	Due to the nature of the intervention, the personnel were not blinded. Because an extra 15 mL blood sample was obtained from the participants in the PRGF group, the participants were most likely not blinded.

Interventions for managing medication-related osteonecrosis of the jaw (Review)

Mozzati 2012 (Continued)

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	High risk	It is not reported whether outcome was monitored by an independent and blinded outcome assessor. Outcome was most likely assessed by the surgeon who had performed the dental extraction.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Completeness or loss to follow-up was not reported.
Selective reporting (reporting bias)	Low risk	The outcomes mentioned in the Methods were all reported.

Mozzati 2013

Methods	<ul style="list-style-type: none"> • Trial design: single-centre, interventional, prospective, unblinded, two-arm randomised controlled trial • Duration of study: from January 2005 to April 2011 • Follow-up: between 12 and 72 months • Sample size calculation: not provided • Country of origin: Italy • Year of publication: 2013 • Language of the original publication: English • Category: prophylaxis of MRONJ • Funding: not reported • Registration in a public trials registry: not stated
Participants	<ul style="list-style-type: none"> • 700 participants receiving oral bisphosphonates: tooth extractions were performed in 334 participants with protocol A (delicate surgery and closure by primary intention), in 366 participants with protocol B (non-traumatic avulsion and closure by secondary intention). • Age 50-60 yr: protocol A 85, protocol B 93. • Age 60-70 yr: protocol A 185, protocol B 179. • Age 70-80 yr: protocol A 64, protocol B 94. • Sex: protocol A 96% female, protocol B 98% female. • Condition treated with bisphosphonates: osteoporosis, rheumatoid arthritis, Paget disease • Inclusion criteria: <ul style="list-style-type: none"> * Current oral bisphosphonate therapy * Treatment with oral bisphosphonates for more than 24 months * The necessity for the removal of compromised dental elements • Exclusion criteria: <ul style="list-style-type: none"> * Any previous history of irradiation to the maxillofacial area * Dental extractions before the study period
Interventions	<p>All participants: professional oral hygiene session 1 week before surgery; antibiotics for 6 days starting the evening before surgery</p> <ul style="list-style-type: none"> • Protocol A: the surgical extractions were carried out by intrasulcular incisions and detachment of full thickness flaps to allow wound healing via primary intention. • Protocol B: the extractions were carried out without detachment of full thickness flaps; sockets were filled with absorbable gelatin sponge haemostatic to allow wound healing via secondary intention.
Outcomes	<ul style="list-style-type: none"> • Intraoperative complications • Success rate (absence of postoperative MRONJ)

Mozzati 2013 (Continued)

Follow-up examinations: mucosal healing was monitored at 3, 7, and 14 days postoperatively; monitoring for MRONJ was continued at 21, 30, 60, and 90 days, and 6 months, followed by visits every 6 months.

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Each patient was assigned by a computer-randomization program to one of two groups."
Allocation concealment (selection bias)	Unclear risk	Concealment of allocation not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	Due to the nature of the intervention, the personnel and participants were not blinded.
Blinding of outcome assessment (detection bias) All outcomes	High risk	At least during the mucosal healing period, due to the nature of the intervention, blinding of outcome assessors is not possible.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Completeness or loss to follow-up was not reported.
Selective reporting (reporting bias)	Low risk	The outcomes mentioned in the Methods were all reported.

Mücke 2016

Methods	<ul style="list-style-type: none"> • Trial design: single-centre, prospective, unblinded, two-arm, randomised controlled trial • Duration of study: enrolment period from 2008 to 2014 • Follow-up: quote: "The mean application period of zoledronic acid was 28.8 months" • Sample size calculation: not provided • Country of origin: Germany • Year of publication: 2016 • Language of the original publication: English • Category: prophylaxis of MRONJ • Funding: no extramural funding; quotation: "The study was not funded" • Registration in a public trials registry: not stated
Participants	<ul style="list-style-type: none"> • 253 men with prostate cancer with planned zoledronic acid for treatment of bone metastases were randomised into 2 groups: 127 in group A and 126 in group B • Mean age: group A 69 yr, group B 72 yr • Sex: male • Condition treated with IV zoledronic acid: metastatic adenocarcinoma of the prostate with bone metastases • Inclusion criteria <ul style="list-style-type: none"> * Metastatic adenocarcinoma of the prostate with bone metastases * Not yet treated with IV zoledronic acid

Mücke 2016 (Continued)

- Exclusion criteria
 - * Kidney failure (creatinine clearance < 30 mL/min)

Interventions	<ul style="list-style-type: none"> Group A (control): participants received an initial examination at the study centre and were monitored and treated where deemed necessary by the individual's dentist, and were re-evaluated once a year. Group B (experimental): participants received an initial examination and were treated if needed at the study centre. Participants were monitored and treated where necessary by the authors at 12-week intervals. Extractions were performed under prophylactic antibiotic treatment and wound closure was carried out without tension on the local flap
Outcomes	<ul style="list-style-type: none"> Incidence rate per year for MRONJ Incidence proportion for MRONJ

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "All patients were prospectively examined before the start of therapy with zoledronic acid and were randomly allocated into two groups." Generation of randomisation sequence not reported
Allocation concealment (selection bias)	Unclear risk	Concealment of allocation not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	"treatment was not possible to be blinded"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not blinded
Incomplete outcome data (attrition bias) All outcomes	High risk	High and unbalanced rate of crossovers: "36 patients, who were randomized to participate in group B did not want to be part of a close follow-up and were then regrouped in group A." "At the end of this study, 153 (93.3%) patients of group A and 79 (87.8%) patients from group B have died." Data analysis: as-treated, not by intention-to-treat.
Selective reporting (reporting bias)	Low risk	The outcomes mentioned in the Methods were all reported.

Ristow 2016

Methods	<ul style="list-style-type: none"> Trial design: single-centre, prospective, unblinded, two-arm, randomised controlled trial Duration of study: quote: "patients [...] were recruited over a time period of 12 months and followed up for 12 months" Follow-up: one year Sample size calculation: not provided; quote: "Because of the preliminary 'proof-of-concept' character of this study, the sample size estimation was disclaimed"
---------	---

Ristow 2016 (Continued)

	<ul style="list-style-type: none"> Country of origin: Germany Year of publication: 2016 Language of the original publication: English Category: treatment of established MRONJ Funding: quote: "There was no source of funding for this research" Registration in a public trials registry: not stated
Participants	<ul style="list-style-type: none"> 40 participants with MRONJ randomised into 2 groups: 20 control (tetracycline fluorescence-guided bone surgery [TF]), 20 experimental (autofluorescence-guided bone surgery [AF]) Mean age: control 67 yr, AF 71 yr Sex: control 69% female, AF 70% female Condition treated with antiresorptive medication: cancer (85% of total sample), osteoporosis (15% of total sample) Inclusion criteria <ul style="list-style-type: none"> * History of antiresorptive drug treatment (bisphosphonates or denosumab, or both) in the absence of radiotherapy to the head and neck region * Exposed osteonecrosis of the jaw, defined as the long-standing (more than 8 weeks) transmucosal exposure of necrotic bone in the jaw Exclusion criteria <ul style="list-style-type: none"> * History of head and neck irradiation * Metastatic bone disease of the maxillofacial region * Contradictions to surgery under general anaesthesia
Interventions	<ul style="list-style-type: none"> Control (TF group): participants received 100 mg doxycycline twice a day for at least 7 days preoperatively. Incorporation of doxycycline into vital bone and absence of doxycycline in necrotic bone was detected by a fluorescent light source (VELscope fluorescence lamp; LED Dental, White Rock, British Columbia, Canada). Doxycycline fluorescence was used for intraoperative identification of bone resection margins and guided debridement of necrotic bone. AF group: participants received antibiotic prophylaxis with ampicillin/sulbactam 2000 mg/1000 mg (or clindamycin 600 mg in case of hypersensitivity to penicillin or a penicillin allergy) before operation. Autofluorescence of vital bone, induced with the VELscope fluorescence lamp (LED Dental, White Rock, British Columbia, Canada) was used for intraoperative identification of bone resection margins and guided debridement of necrotic bone. <p>In all participants, a tension-free wound closure was achieved using mucoperiosteal flaps. All participants remained in hospital for 4 days after the operation. Participants received routine postoperative instructions and the same postoperative analgesic drug therapy. Antibiotic treatment involved the administration of ampicillin/sulbactam 2000 mg/1000 mg (or clindamycin in case of hypersensitivity to penicillin or a penicillin allergy) intravenously while in hospital and then orally for a further 6 days after discharge from the hospital.</p>
Outcomes	<ul style="list-style-type: none"> Primary <ul style="list-style-type: none"> * Success rate: absence of a MRONJ site (i.e. maintenance of full mucosal coverage) at 8 weeks (T2) after surgery Secondary <ul style="list-style-type: none"> * Mucosal integrity at 10 days (T1), 6 months (T3), and 1 year (T4) after surgery * Loss of sensitivity (numbness) of the alveolar nerve (Vincent sign) at 10 days (T1), 8 weeks (T2), 6 months (T3), and 1 year (T4) after surgery * Subjective pain at 10 days (T1), 8 weeks (T2), 6 months (T3), and 1 year (T4) after surgery * Signs of infection at 10 days (T1), 8 weeks (T2), 6 months (T3), and 1 year (T4) after surgery
Notes	
Risk of bias	
Bias	Authors' judgement Support for judgement

Ristow 2016 (Continued)

Random sequence generation (selection bias)	Unclear risk	"Over a period of 12 months, the study population was prospectively referred for the treatment of MRONJ and divided randomly into two study groups" Generation of randomisation sequence not reported
Allocation concealment (selection bias)	Unclear risk	Concealment of allocation not reported
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	4 participants (2 each in the TF and the AF group) died after T2 (8 weeks after the operation) and 2 participants in the AF group failed to attend the 1-year follow-up (T4). No participant was lost for assessment of the primary endpoint at T2 (8 weeks after the operation).
Selective reporting (reporting bias)	Low risk	The outcomes mentioned in the Methods were all reported.

Characteristics of excluded studies [author-defined order]

Study	Reason for exclusion
Asaka 2016	Not an RCT
Bonacina 2011	Not an RCT
Bramati 2015	Not an RCT
Coviello 2012	Not an RCT
DE Iuliis 2014	Not an RCT
Dimopoulos 2009	Not an RCT
Lee 2014	Not an RCT
Montebugnoli 2007	Not an RCT
Pelaz 2014	Not an RCT
Vescovi 2010	Not an RCT
Vescovi 2012	Not an RCT

RCT: randomised clinical trial

Characteristics of ongoing studies [ordered by study ID]

ACTRN12612000950864

Trial name or title	Does teriparatide reverse osteonecrosis of the jaw in patients treated with either bisphosphonates or denosumab? A randomised, controlled trial
Methods	Interventional, randomised, parallel assignment, blinded
Participants	<p>Target sample size: 68</p> <p>All sexes eligible for study, 18 years and older</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Osteonecrosis of the jaw • Previous/current treatment with either bisphosphonates or denosumab <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • Previous craniofacial radiotherapy • Pregnancy • Hypercalcaemia or pre-existing primary hyperparathyroidism • Known metabolic bone disease, excluding osteoporosis or metastatic bone disease • Growth hormone deficiency • Secondary hyperparathyroidism with parathyroid hormone greater than two-fold above upper limit of reference range • Severe renal impairment (estimated glomerular filtration rate < 30 mL/min)
Interventions	<p>Experimental: subcutaneous teriparatide injections (20 µg daily), plus calcium (600 mg tablet daily) and vitamin D (1000 IU tablet daily) supplementation for 8 weeks</p> <p>Control: placebo saline injections, plus calcium (600 mg tablet daily) and vitamin D (1000 IU tablet daily) supplementation for 8 weeks</p>
Outcomes	<p>Primary outcome:</p> <ul style="list-style-type: none"> • Clinical staging of osteonecrosis of the jaw - described by the American Association of Oral and Maxillofacial Surgeons position paper • Radiological staging of osteonecrosis of the jaw, as assessed by cone beam computed tomography <p>Secondary outcome:</p> <ul style="list-style-type: none"> • Bone formation and resorption markers (P1NP¹, beta-CTX²) • Jaw osteoblast activity, as measured by NaF-positron emission tomography imaging • Quality of life
Starting date	September 2012
Contact information	peter.ebeling@monash.edu
Notes	Prof. Ebeling was contacted. The study results will be available in the second half of 2017.

NCT01526915

Trial name or title	Assessment of platelet rich fibrin efficiency on healing delay and on jawbone osteochemonecrosis provoked by bisphosphonates (OCN/PRF)
Methods	Interventional, randomised, parallel assignment, open label
Participants	<p>270 participants are required to validate the expected objectives in this study</p> <p>All sexes eligible for study, 18 years and older</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> Adults (male or female) Documented indication at the initial visit at day 0 (JO) for a maximum extraction of 3 teeth Treatment with nitrogenous or non-nitrogenous bisphosphonate (BP) by intravenous injection or oral administration whatever the reason for this drug prescription: <ul style="list-style-type: none"> * ongoing BP treatment * individual having received a previous treatment with BPs (irrespective of the duration and withdrawal date of this treatment) Individual having received the specific information letter regarding the study and having signed the clarified consent form <p>Exclusion criteria:</p> <ul style="list-style-type: none"> Individual having a maxillary or mandibular OCN³ at day 0 (JO) Positive HIV serology at Day 0 (for participants belonging to the platelet-rich fibrin (PRF) group) Previous history of maxillo-cervico-facial radiotherapy Individual with estimated survival expectancy shorter than one year Lack of social security cover Inability of the individual to respect the study follow-up Individual having reached his/her majority and under tutelage, trusteeship or protection of the court Individual whose diagnosis could not be revealed to him/her (especially when the individual or the family expressed this wish)
Interventions	<p>Experimental: bone curettage + PRF insertion</p> <p>Control: bone curettage alone without PRF insertion</p>
Outcomes	<p>Primary outcome measures:</p> <ul style="list-style-type: none"> Delay in cicatrisation⁴ at week 8 The appearance of osteochemonecrosis during the follow-up period <p>Secondary outcome measures:</p> <ul style="list-style-type: none"> The characteristics of the received BP treatment: starting date of ongoing treatment, accumulated dose, type of BP, administration route The precise location of the extraction site according to the tooth classification number
Starting date	September 2011
Contact information	e.gerard@chr-metz-thionville.fr
Notes	

NCT02198001

Trial name or title	Prospective randomized study: assessment of PRF efficacy in prevention of jaw osteonecrosis after tooth extraction (PRF)
Methods	Interventional; randomised; parallel assignment, blinded
Participants	<p>Cohort of 100 participants: control group 50 participants and experimental 50 participants</p> <p>All sexes eligible for study; 50 years and older</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Individuals taking bisphosphonates whatever the indication, the type, the administration and the duration of treatment (we include those taking or having taken bisphosphonates, even several years ago) • Individuals who need tooth extraction (not recoverable in conservative dentistry and symptomatic tooth: dental and periodontal infections, symptomatic traumatic tooth fracture) <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • Pregnant women • Younger than 50 years old • Aw's radiotherapy • History of jaw osteonecrosis • Aw metastasis from another cancer
Interventions	<p>Experimental: tooth extraction and insertion of PRF (non-traumatic tooth extraction with antibiotics (amoxicillin clavulanate combination). Insertion of PRF membrane in tooth-extraction site)</p> <p>Control: no PRF (non-traumatic extraction with antibiotic without PRF insertion)</p>
Outcomes	Number of participants with jaw osteonecrosis after tooth extraction
Starting date	January 2014
Contact information	dorothee.deneubourg@uclouvain.be, michele.magremanne@uclouvain.be
Notes	

UMIN000009132

Trial name or title	Study to the effect of teriparatide formulation Forteo versus Teribone on bisphosphonate-related osteonecrosis of the jaw in osteoporosis patients
Methods	Interventional, parallel, randomised, open study
Participants	<p>15 female participants ≥ 20 years of age</p> <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Individuals who require continued treatment for osteoporosis • Females with bisphosphonate-related osteonecrosis of the jaw • Bisphosphonate-related osteonecrosis of the jaw stage 2 or more • Outpatients • Signed informed consent forms obtained <p>Exclusion criteria:</p>

UMIN000009132 (Continued)

- Hypercalcaemic disorders
- Potential risk of osteosarcoma
- Individuals with Paget's disease of bone
- Unexplained elevations of alkaline phosphatase
- Young adults with open epiphyses
- Individuals with prior external beam or implant radiation involving the skeleton
- Individuals with bone metastases, history of skeletal malignancies
- Metabolic bone diseases other than osteoporosis
- Pregnancy or women with suspected pregnancy
- Individuals with hypersensitivity to teriparatide or to any of its excipients
- Serious cardiac disease, serious hepatic disorder, renal disease
- Use of active vitamin D3 or digoxin
- Individuals who could not provide informed consent
- Unsuitability for the trial based on clinical judgement

Interventions	Forteo (teriparatide) vs Teribone (teriparatide)
Outcomes	<ul style="list-style-type: none"> • pain • bone formation
Starting date	August 2012
Contact information	yumiko@med.kagawa-u.ac.jp
Notes	

1. P1NP, N-terminal propeptide of type 1 collagen Procollagen I Intact N-Terminal
2. Beta-CTX, Beta-carboxy-terminal telopeptide of type 1 collagen (beta-CrossLaps)
3. OCN: osteochemonecrosis
4. Cicatrisation: formation of scar tissue at a wound site by fibroblasts

DATA AND ANALYSES

Comparison 1. Dental examinations at three-month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 MRONJ (incidence proportion)	1	253	Risk Ratio (M-H, Fixed, 95% CI)	0.10 [0.02, 0.39]
2 MRONJ (incidence rate: MRONJ cases per patient-year)	1		Rate ratio (Fixed, 95% CI)	0.18 [0.04, 0.74]

Analysis 1.1. Comparison 1 Dental examinations at three-month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 1 MRONJ (incidence proportion).

Analysis 1.2. Comparison 1 Dental examinations at three-month intervals and preventive treatments (experimental) versus standard care (control) for prophylaxis of MRONJ, Outcome 2 MRONJ (incidence rate: MRONJ cases per patient-year).

Comparison 2. A dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) versus a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 MRONJ (incidence proportion)	1	176	Risk Ratio (M-H, Random, 95% CI)	0.08 [0.00, 1.51]

Analysis 2.1. Comparison 2 A dental extraction protocol with plasma rich in growth factors (PRGF) (experimental) versus a standard dental extraction protocol without PRGF (control) for prophylaxis of MRONJ in people treated with IV bisphosphonates who need dental extractions, Outcome 1 MRONJ (incidence proportion).

Comparison 3. Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Healing of MRONJ at last contact	1	46	Risk Ratio (M-H, Fixed, 95% CI)	1.56 [0.77, 3.18]

Analysis 3.1. Comparison 3 Hyperbaric oxygen as an adjunct to conventional therapy (experimental) versus conventional therapy (control) for treatment of MRONJ, Outcome 1 Healing of MRONJ at last contact.

Comparison 4. Autofluorescence-guided bone surgery (experimental) versus tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Healing of MRONJ (defined as mucosal integrity) at 1 year	1	34	Risk Ratio (M-H, Fixed, 95% CI)	1.05 [0.86, 1.30]

Analysis 4.1. Comparison 4 Autofluorescence-guided bone surgery (experimental) versus tetracycline fluorescence-guided bone surgery (control) for treatment of MRONJ, Outcome 1 Healing of MRONJ (defined as mucosal integrity) at 1 year.

ADDITIONAL TABLES

Table 1. Clinical staging of MRONJ

MRONJ stage	Description
AT RISK	No apparent necrotic bone in patients who have been treated with oral or intravenous bisphosphonates
STAGE 0	No clinical evidence of necrotic bone but nonspecific clinical findings, radiographic changes, and symptoms
STAGE 1	Exposed and necrotic bone or fistulas that probes to bone in patients who are asymptomatic and have no evidence of infection
STAGE 2	Exposed and necrotic bone or fistulas that probes to bone associated with infection as evidenced by pain and erythema in the region of exposed bone with or without purulent drainage
STAGE 3	Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and ≥ 1 of the following: exposed and necrotic bone extending beyond the region of alveolar bone (i.e. inferior border and ramus in mandible, maxillary sinus, and zygoma in maxilla) resulting in pathologic fracture, extraoral fistula, oral antral, or oral nasal communication, or osteolysis extending to inferior border of the mandible or sinus floor

From the American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update ([Ruggiero 2014](#))

APPENDICES

Appendix 1. Cochrane Oral Health's Trials Register search strategy

- 1 (((medication or bisphosphonate or drug) and (osteonecrosis or necrosis) and jaw*)):ti,ab) AND (INREGISTER)
- 2 (MRONJ or BRONJ or BONJ:ti,ab) AND (INREGISTER)
- 3 (#1 or #2) AND (INREGISTER)
- 4 ((osteonecrosis or "bone necrosis"):ti,ab) AND (INREGISTER)
- 5 (osteochemonecro*:ti,ab) AND (INREGISTER)
- 6 (#4 or #5) AND (INREGISTER)
- 7 ((jaw* or jawbone* or mandib* or maxill* or (alveolar and bone*)):ti,ab) AND (INREGISTER)
- 8 ((diphosphonate* or bisphosphonate* or aminobisphosphonate* or alendronate or risedronate or pamidronate or "zoledronic acid" or ibandronate or "alendronic acid" or bevacizumab or denosumab or "etidronate disodium" or "ibandronic acid" or sirolimus or "sodium clodronate" or sorafenib or sunitinib or "tiludronic acid" or zoledronate or didronel or "clodronate disodium" or tiludronate or "risedronic acid" or "clodronic acid"):ti,ab) AND (INREGISTER)
- 9 ((Fosamax or Fosavance or Actonel or Aclasta or Zometa or Reclast or Didronel or Skelid or Bondronat or Bonviva or Aredia or Bonefos or Nexavar or Avastin or Prolia or Xgeva or Boniva or Atelvia or Rapamune or Rapamycin or Sutent or Zometa):ti,ab) AND (INREGISTER)
- 10 ((denosumab or prolia or ranmark or xgeva):ti,ab) AND (INREGISTER)
- 11 ((antivegf of avastin or bevacizumab):ti,ab) AND (INREGISTER)

- 12 ((aflibercept or eylea or "vegfr trap" or zaltrap):ti,ab) AND (INREGISTER)
- 13 (("su 11248" or sunitinib or sunitinibum or sutent):ti,ab) AND (INREGISTER)
- 14 (("bms 907351" or bms907351 or cabozantinib or cometriq or "xl 184" or "xl 184" or xl184):ti,ab) AND (INREGISTER)
- 15 ((temsirolimus or torisel):ti,ab) AND (INREGISTER)
- 16 ((afinitor or certican or everolimus or everolimus or rad001 or "sdz rad" or votubia or zortress):ti,ab) AND (INREGISTER)
- 17 (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16) AND (INREGISTER)
- 18 (#6 and #7 and #17) AND (INREGISTER)
- 19 (#3 or #18) AND (INREGISTER)

Appendix 2. Cochrane Central Register of Controlled Clinical Trials (CENTRAL) search strategy

- #1 [mh ^"Bisphosphonate-associated osteonecrosis of the jaw"]
- #2 ((medication or bisphosphonate or drug) near/4 (osteonecrosis or necrosis) near/3 jaw*)
- #3 (MRONJ or BRONJ or BONJ):ti,ab
- #4 {or #1-#3}
- #5 [mh ^Osteonecrosis]
- #6 (osteonecro* or "bone necrosis"):ti,ab
- #7 osteochemonecro*:ti,ab
- #8 {or #5-#7}
- #9 [mh jaw]
- #10 [mh ^"alveolar bone loss"]
- #11 [mh ^"jaw diseases"]
- #12 (jaw* or jawbone* or mandib* or maxill* or (alveolar near/4 bone*)):ti,ab
- #13 {or #9-#12}
- #14 [mh diphosphonates]
- #15 (diphosphonate* or bisphosphonate* or aminobisphosphonate* or alendronate or risedronate or pamidronate or "zoledronic acid" or ibandronate or "alendronic acid" or bevacizumab or denosumab or "etidronate disodium" or "ibandronic acid" or sirolimus or "sodium clodronate" or sorafenib or sunitinib or "tiludronic acid" or zoledronate or didronel or "clodronate disodium" or tiludronate or "risedronic acid" or "clodronic acid"):ti,ab
- #16 (Fosamax or Fosavance or Actonel or Aclasta or Zometa or Reclast or Didronel or Skelid or Bondronat or Bonviva or Aredia or Bonefos or Nexavar or Avastin or Prolia or Xgeva or Boniva or Atelvia or Rapamune or Rapamycin or Sutent or Zometa):ti,ab
- #17 [mh ^Denosumab]
- #18 (denosumab or prolia or ranmark or xgeva):ti,ab
- #19 [mh ^Bevacizumab]
- #20 (antivegf of avastin or bevacizumab):ti,ab
- #21 (aflibercept or eylea or "vegfr trap" or zaltrap):ti,ab
- #22 ("su 11248" or sunitinib or sunitinibum or sutent):ti,ab
- #23 ("bms 907351" or bms907351 or cabozantinib or cometriq or "xl 184" or "xl 184" or xl184):ti,ab
- #24 (temsirolimus or torisel):ti,ab
- #25 [mh ^Everolimus]
- #26 (afinitor or certican or everolimus or everolimus or rad001 or "sdz rad" or votubia or zortress):ti,ab
- #27 {or #14-#26}
- #28 #8 and #13 and #27
- #29 #4 or #28

Appendix 3. MEDLINE Ovid search strategy

1. Bisphosphonate-associated osteonecrosis of the jaw/
2. ((medication or bisphosphonate or drug) adj4 (osteonecrosis or necrosis) adj3 jaw\$).ti,ab.
3. (MRONJ or BRONJ or BONJ).ti,ab.
4. or/1-3
5. Osteonecrosis/
6. (osteonecro\$ or "bone necrosis").ti,ab.
7. osteochemonecro\$.ti,ab.
8. or/5-7
9. exp Jaw/
10. Alveolar bone loss/ci
11. Jaw diseases/ci
12. (jaw or jawbone\$ or mandibl\$ or maxill\$ or (alveolar adj4 bone\$)).ti,ab.
13. or/9-12
14. exp Diphosphonates/
15. (diphosphonate\$ or bisphosphonate\$ or aminobisphosphonate\$ or alendronate or risedronate or pamidronate or "zoledronic acid" or ibandronate or "alendronic acid" or bevacizumab or denosumab or "etidronate disodium" or "ibandronic acid" or sirolimus or "sodium

clodronate" or sorafenib or sunitinib or "tiludronic acid" or zoledronate or didronel or "clodronate disodium" or tiludronate or "risedronic acid" or "clodronic acid").ti,ab

16. (Fosamax or Fosavance or Actonel or Aclasta or Zometa or Reclast or Didronel or Skelid or Bondronat or Bonviva or Aredia or Bonefos or Nexavar or Avastin or Prolia or Xgeva or Boniva or Atelvia or Rapamune or Rapamycin or Sutent or Zometa).ti,ab.

17. Denosumab/

18. (denosumab or prolia or ranmark or xgeva).ti,ab.

19. Bevacizumab/

20. (antivegf or avastin or bevacizumab).ti,ab.

21. (aflibercept or eylea or "vegf trap" or zaltrap).ti,ab.

22. ("su 11248" or sunitinib or sunitinibum or sutent).ti,ab.

23. ("bms 907351" or bms907351 or cabozantinib or cometriq or "xl 184" or "xl 184" or xl184).ti,ab.

24. (temsirolimus or torisel).ti,ab.

25. Everolimus/

26. (afinitor or certican or everolimus or everolimus or rad001 or "sdz rad" or votubia or zortress).ti,ab.

27. or/14-26

28. 8 and 13 and 27

29. 4 or 28

The search will be done with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of *The Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011] ([Lefebvre 2011](#)).

1. randomized controlled trial.pt.

2. controlled clinical trial.pt.

3. randomized.ab.

4. placebo.ab.

5. drug therapy.fs.

6. randomly.ab.

7. trial.ab.

8. groups.ab.

9. or/1-8

10. exp animals/ not humans.sh.

11. 9 not 10

Appendix 4. Embase Ovid search strategy

1. ((medication or bisphosphonate or drug) adj4 (osteonecrosis or necrosis) adj3 jaw\$).ti,ab.

2. (MRONJ or BRONJ or BONJ).ti,ab.

3. 1 or 2

4. "Bone necrosis"/

5. "Jaw osteonecrosis"/

6. (osteonecro\$ or "bone necrosis").ti,ab.

7. osteochemonecro\$.ti,ab.

8. or/4-6

9. exp Jaw/

10. Alveolar bone loss/

11. Jaw disease/

12. (jaw or jawbone\$ or mandibl\$ or maxill\$ or (alveolar adj4 bone\$)).ti,ab.

13. or/9-12

14. exp Bisphosphonic acid derivative/

15. (diphosphonate\$ or bisphosphonate\$ or aminobisphosphonate\$ or alendronate or risedronate or pamidronate or "zoledronic acid" or ibandronate or "alendronic acid" or bevacizumab or denosumab or "etidronate disodium" or "ibandronic acid" or sirolimus or "sodium clodronate" or sorafenib or sunitinib or "tiludronic acid" or zoledronate ordidronel or "clodronate disodium" or tiludronate or "risedronic acid" or "clodronic acid").ti,ab.

16. (Fosamax or Fosavance or Actonel or Aclasta or Zometa or Reclast or Didronel or Skelid or Bondronat or Bonviva or Aredia or Bonefos or Nexavar or Avastin or Prolia or Xgeva or Boniva or Atelvia or Rapamune or Rapamycin or Sutent or Zometa).ti,ab.

17. Denosumab/

18. (denosumab or prolia or ranmark or xgeva).ti,ab.

19. Bevacizumab/

20. (antivegf or avastin or bevacizumab).ti,ab.

21. (aflibercept or eylea or "vegf trap" or zaltrap).ti,ab.

22. ("su 11248" or sunitinib or sunitinibum or sutent).ti,ab.

23. ("bms 907351" or bms907351 or cabozantinib or cometriq or "xl 184" or "xl 184" or xl184).ti,ab.
24. (temsirolimus or torisel).ti,ab.
25. Everolimus/
26. (afinitor or certican or everolimus or everolimus or rad001 or "sdz rad" or votubia or zortress).ti,ab.
27. or/14-26
28. 8 and 13 and 27
29. 3 or 28

The above subject search was linked to adapted version of the Cochrane Crowd Project filter for identifying RCTs in Embase Ovid (see <http://www.cochranelibrary.com/help/central-creation-details.html> for information):

1. Randomized controlled trial/
2. Controlled clinical study/
3. Random\$.ti,ab.
4. randomization/
5. intermethod comparison/
6. placebo.ti,ab.
7. (compare or compared or comparison).ti.
8. ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
9. (open adj label).ti,ab.
10. ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
11. double blind procedure/
12. parallel group\$1.ti,ab.
13. (crossover or cross over).ti,ab.
14. ((assign\$ or match or matched or allocation) adj5 (alternate or group\$1 or intervention\$1 or patient\$1 or subject\$1 or participant \$1)).ti,ab.
15. (assigned or allocated).ti,ab.
16. (controlled adj7 (study or design or trial)).ti,ab.
17. (volunteer or volunteers).ti,ab.
18. trial.ti.
19. or/1-18
20. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
21. 19 not 20

Appendix 5. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) search strategy

bisphosphonates and jaw
osteonecrosis and jaw
necrosis and jaw

Appendix 6. World Health Organization International Clinical Trials Registry Platform search strategy

bisphosphonates and jaw
osteonecrosis and jaw or necrosis and jaw

CONTRIBUTIONS OF AUTHORS

Drafted the protocol: NB, OZ
Wrote the protocol: NB, OZ
Developed the search strategy: NB, OZ, and Anne Littlewood (Trials Search Co-ordinator from the Cochrane Oral Health Group)
Searched for trials: NB, HH, OZ
Extracted data: NB, HH, OZ
Assessed trial for risk of bias: NB, HH, OZ
Assessed quality of the evidence: NB, OZ
Contacted authors of ongoing RCTs: OZ
Performed statistical analysis: NB, BM, OZ
Wrote the review: NB, OZ
Produced 'Summary of findings' table: NB, OZ

DECLARATIONS OF INTEREST

There are no financial conflicts of interest and the review authors declare that they do not have any associations with any parties who may have vested interests in the results of this review.

- Natalie H Beth-Tasdogan: no interests to declare
- Benjamin Mayer: no interests to declare
- Heba Hussein: no interests to declare
- Oliver Zolk: no interests to declare

SOURCES OF SUPPORT

Internal sources

- Institute of Pharmacology of Natural Products & Clinical Pharmacology, and Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
- Oral Medicine, Diagnosis, and Periodontology Department, Faculty of Dentistry, Cairo University, Egypt.

External sources

- National Institute for Health Research (NIHR), UK.

This project was supported by the NIHR, via Cochrane Infrastructure funding to Cochrane Oral Health. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

- Cochrane Oral Health Global Alliance, Other.

The production of Cochrane Oral Health reviews has been supported financially by our Global Alliance since 2011 (ohg.cochrane.org/partnerships-alliances). Contributors over the past year have been: British Association for the Study of Community Dentistry, UK; British Society of Paediatric Dentistry, UK; the Canadian Dental Hygienists Association, Canada; Centre for Dental Education and Research at All India Institute of Medical Sciences, India; National Center for Dental Hygiene Research & Practice, USA; New York University College of Dentistry, USA; NHS Education for Scotland, UK; Swiss Society for Endodontology, Switzerland

INDEX TERMS

Medical Subject Headings (MeSH)

Angiogenesis Inhibitors [adverse effects]; Anti-Bacterial Agents [therapeutic use]; Bisphosphonate-Associated Osteonecrosis of the Jaw [prevention & control] [therapy]; Bone Density Conservation Agents [adverse effects] [therapeutic use]; Denosumab [adverse effects] [therapeutic use]; Dental Care; Diphosphonates [adverse effects] [therapeutic use]; Hyperbaric Oxygenation; Imidazoles [adverse effects] [therapeutic use]; Intercellular Signaling Peptides and Proteins [therapeutic use]; Jaw Diseases [*chemically induced] [prevention & control] [*therapy]; Oral Health; Osteonecrosis [*chemically induced] [prevention & control] [*therapy]; Postoperative Complications [prevention & control] [therapy]; Prostatic Neoplasms [drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Tooth Extraction [adverse effects]; Zoledronic Acid

MeSH check words

Female; Humans; Male